{
"NDC": [
{
"NDCCode": "76233-277-20",
"PackageDescription": "10 VIAL, SINGLE-DOSE in 1 CARTON (76233-277-20) > 15 mL in 1 VIAL, SINGLE-DOSE (76233-277-00) ",
"NDC11Code": "76233-0277-20",
"ProductNDC": "76233-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Piperacillin And Tazobactam",
"NonProprietaryName": "Piperacillin And Tazobactam",
"DosageFormName": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
"RouteName": "INTRAVENOUS",
"StartMarketingDate": "20200724",
"MarketingCategoryName": "ANDA",
"ApplicationNumber": "ANDA203768",
"LabelerName": "Laboratorio Reig Jofre Sa.",
"SubstanceName": "PIPERACILLIN SODIUM; TAZOBACTAM SODIUM",
"StrengthNumber": "3; .375",
"StrengthUnit": "g/15mL; g/15mL",
"Pharm_Classes": "Penicillin-class Antibacterial [EPC],Penicillins [CS],beta Lactamase Inhibitors [MoA],beta Lactamase Inhibitor [EPC]",
"Status": "Deprecated",
"LastUpdate": "2021-07-28",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20211231",
"StartMarketingDatePackage": "20200724",
"SamplePackage": "N"
},
{
"NDCCode": "76233-091-01",
"PackageDescription": "1 VIAL, SINGLE-USE in 1 CARTON (76233-091-01) > 20 mL in 1 VIAL, SINGLE-USE",
"NDC11Code": "76233-0091-01",
"ProductNDC": "76233-091",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Daptomycin",
"NonProprietaryName": "Daptomycin",
"DosageFormName": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
"RouteName": "INTRAVENOUS",
"StartMarketingDate": "20210203",
"MarketingCategoryName": "ANDA",
"ApplicationNumber": "ANDA210057",
"LabelerName": "Laboratorio Reig Jofre, S.A.",
"SubstanceName": "DAPTOMYCIN",
"StrengthNumber": "500",
"StrengthUnit": "mg/10mL",
"Pharm_Classes": "Lipopeptide Antibacterial [EPC],Lipopeptides [CS]",
"Status": "Deprecated",
"LastUpdate": "2021-08-24",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20211231",
"StartMarketingDatePackage": "20210203",
"SamplePackage": "N"
},
{
"NDCCode": "76233-091-05",
"PackageDescription": "5 VIAL, SINGLE-USE in 1 CARTON (76233-091-05) > 20 mL in 1 VIAL, SINGLE-USE",
"NDC11Code": "76233-0091-05",
"ProductNDC": "76233-091",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Daptomycin",
"NonProprietaryName": "Daptomycin",
"DosageFormName": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
"RouteName": "INTRAVENOUS",
"StartMarketingDate": "20210203",
"MarketingCategoryName": "ANDA",
"ApplicationNumber": "ANDA210057",
"LabelerName": "Laboratorio Reig Jofre, S.A.",
"SubstanceName": "DAPTOMYCIN",
"StrengthNumber": "500",
"StrengthUnit": "mg/10mL",
"Pharm_Classes": "Lipopeptide Antibacterial [EPC],Lipopeptides [CS]",
"Status": "Deprecated",
"LastUpdate": "2021-08-24",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20211231",
"StartMarketingDatePackage": "20210203",
"SamplePackage": "N"
},
{
"NDCCode": "76233-278-20",
"PackageDescription": "10 VIAL, SINGLE-DOSE in 1 CARTON (76233-278-20) > 20 mL in 1 VIAL, SINGLE-DOSE (76233-278-00) ",
"NDC11Code": "76233-0278-20",
"ProductNDC": "76233-278",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Piperacillin And Tazobactam",
"NonProprietaryName": "Piperacillin And Tazobactam",
"DosageFormName": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
"RouteName": "INTRAVENOUS",
"StartMarketingDate": "20200724",
"MarketingCategoryName": "ANDA",
"ApplicationNumber": "ANDA203768",
"LabelerName": "Laboratorio Reig Jofre Sa.",
"SubstanceName": "PIPERACILLIN SODIUM; TAZOBACTAM SODIUM",
"StrengthNumber": "4; .5",
"StrengthUnit": "g/20mL; g/20mL",
"Pharm_Classes": "Penicillin-class Antibacterial [EPC],Penicillins [CS],beta Lactamase Inhibitors [MoA],beta Lactamase Inhibitor [EPC]",
"Status": "Deprecated",
"LastUpdate": "2021-07-28",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20211231",
"StartMarketingDatePackage": "20200724",
"SamplePackage": "N"
},
{
"NDCCode": "76233-279-20",
"PackageDescription": "10 VIAL, SINGLE-DOSE in 1 CARTON (76233-279-20) > 10 mL in 1 VIAL, SINGLE-DOSE (76233-279-00) ",
"NDC11Code": "76233-0279-20",
"ProductNDC": "76233-279",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Piperacillin And Tazobactam",
"NonProprietaryName": "Piperacillin And Tazobactam",
"DosageFormName": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
"RouteName": "INTRAVENOUS",
"StartMarketingDate": "20200724",
"MarketingCategoryName": "ANDA",
"ApplicationNumber": "ANDA203768",
"LabelerName": "Laboratorio Reig Jofre Sa.",
"SubstanceName": "PIPERACILLIN SODIUM; TAZOBACTAM SODIUM",
"StrengthNumber": "2; .25",
"StrengthUnit": "g/10mL; g/10mL",
"Pharm_Classes": "Penicillin-class Antibacterial [EPC],Penicillins [CS],beta Lactamase Inhibitors [MoA],beta Lactamase Inhibitor [EPC]",
"Status": "Deprecated",
"LastUpdate": "2021-07-28",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20211231",
"StartMarketingDatePackage": "20200724",
"SamplePackage": "N"
},
{
"NDCCode": "10544-277-20",
"PackageDescription": "20 TABLET in 1 BOTTLE (10544-277-20)",
"NDC11Code": "10544-0277-20",
"ProductNDC": "10544-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Naproxen",
"NonProprietaryName": "Naproxen",
"DosageFormName": "TABLET",
"RouteName": "ORAL",
"StartMarketingDate": "20091214",
"MarketingCategoryName": "ANDA",
"ApplicationNumber": "ANDA078250",
"LabelerName": "Blenheim Pharmacal, Inc.",
"SubstanceName": "NAPROXEN",
"StrengthNumber": "375",
"StrengthUnit": "mg/1",
"Pharm_Classes": "Cyclooxygenase Inhibitors [MoA],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC]",
"Status": "Deprecated",
"LastUpdate": "2019-09-21",
"ProductNdcExcludeFlag": "E",
"ListingRecordCertifiedThrough": "20171231",
"IndicationAndUsage": "Carefully consider the potential benefits and risks of naproxen, naproxen sodium and other treatment options before deciding to use naproxen and naproxen sodium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS). Naproxen as naproxen or naproxen sodium tablets are indicated: : 1 For the relief of the signs and symptoms of rheumatoid arthritis , 2 For the relief of the signs and symptoms of osteoarthritis , 3 For the relief of the signs and symptoms of ankylosing spondylitis , 4 For the relief of the signs and symptoms of juvenile arthritis.",
"Description": "Naproxen USP is a proprionic acid derivative related to the arylacetic acid group of nonsteroidal anti-inflammatory drugs. The chemical names for naproxen USP and naproxen sodium USP are (S)-6-methoxy-α-methyl-2-naphthaleneacetic acid and (S)-6-methoxy-α-methyl-2-naphthaleneacetic acid, sodium salt, respectively. Naproxen USP and naproxen sodium USP have the following structures, respectively:. Naproxen USP has a molecular weight of 230.26 and a molecular formula of C14H14O3. Naproxen sodium USP has a molecular weight of 252.23 and a molecular formula of C14H13NaO3. Naproxen USP is an odorless, white to off-white crystalline substance. It is lipid-soluble, practically insoluble in water at low pH and freely soluble in water at high pH. The octanol/water partition coefficient of naproxen USP at pH 7.4 is 1.6 to 1.8. Naproxen sodium USP is a white to creamy white, crystalline solid, freely soluble in water at neutral pH. Naproxen tablets USP are available as light orange colored tablets containing 250 mg of naproxen USP, light orange colored tablets containing 375 mg of naproxen USP and light orange colored tablets containing 500 mg of naproxen USP for oral administration. The inactive ingredients are microcrystalline cellulose, croscarmellose sodium, iron oxides, povidone and magnesium stearate. Naproxen sodium tablets USP are available as blue tablets containing 275 mg of naproxen sodium USP and as blue tablets containing 550 mg of naproxen sodium USP for oral administration. The inactive ingredients are croscarmellose sodium, colloidal silicon dioxide, povidone, magnesium stearate, microcrystalline cellulose and talc. The coating suspension for the naproxen sodium 275 mg tablet may contain Opadry blue 03F50544. The coating suspension for the naproxen sodium 550 mg tablet may contain Opadry blue 03F50544."
},
{
"NDCCode": "43744-277-20",
"PackageDescription": "15 g in 1 DRUM (43744-277-20)",
"NDC11Code": "43744-0277-20",
"ProductNDC": "43744-277",
"ProductTypeName": "BULK INGREDIENT",
"NonProprietaryName": "Diclofenac Sodium",
"DosageFormName": "POWDER",
"StartMarketingDate": "20120808",
"EndMarketingDate": "20130624",
"MarketingCategoryName": "BULK INGREDIENT",
"LabelerName": "CBSCHEM LIMITED",
"SubstanceName": "DICLOFENAC SODIUM",
"StrengthNumber": "1",
"StrengthUnit": "g/g",
"Status": "Deprecated",
"LastUpdate": "2014-02-04",
"ListingRecordCertifiedThrough": "20130624"
},
{
"NDCCode": "43744-277-22",
"PackageDescription": "20 g in 1 DRUM (43744-277-22)",
"NDC11Code": "43744-0277-22",
"ProductNDC": "43744-277",
"ProductTypeName": "BULK INGREDIENT",
"NonProprietaryName": "Diclofenac Sodium",
"DosageFormName": "POWDER",
"StartMarketingDate": "20120808",
"EndMarketingDate": "20130624",
"MarketingCategoryName": "BULK INGREDIENT",
"LabelerName": "CBSCHEM LIMITED",
"SubstanceName": "DICLOFENAC SODIUM",
"StrengthNumber": "1",
"StrengthUnit": "g/g",
"Status": "Deprecated",
"LastUpdate": "2014-02-04",
"ListingRecordCertifiedThrough": "20130624"
},
{
"NDCCode": "49999-277-20",
"PackageDescription": "20 TABLET in 1 BOTTLE, PLASTIC (49999-277-20)",
"NDC11Code": "49999-0277-20",
"ProductNDC": "49999-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Hydrocodone Bitartrate And Acetaminophen",
"NonProprietaryName": "Hydrocodone Bitartrate And Acetaminophen",
"DosageFormName": "TABLET",
"RouteName": "ORAL",
"StartMarketingDate": "20110205",
"MarketingCategoryName": "ANDA",
"ApplicationNumber": "ANDA040084",
"LabelerName": "Lake Erie Medical DBA Quality Care Products LLC",
"SubstanceName": "HYDROCODONE BITARTRATE; ACETAMINOPHEN",
"StrengthNumber": "10; 650",
"StrengthUnit": "mg/1; mg/1",
"Pharm_Classes": "Opioid Agonist [EPC],Opioid Agonists [MoA]",
"DEASchedule": "CIII",
"Status": "Deprecated",
"LastUpdate": "2016-03-11"
},
{
"NDCCode": "51079-277-20",
"PackageDescription": "100 BLISTER PACK in 1 BOX, UNIT-DOSE (51079-277-20) > 1 TABLET in 1 BLISTER PACK (51079-277-01)",
"NDC11Code": "51079-0277-20",
"ProductNDC": "51079-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Propranolol Hydrochloride",
"NonProprietaryName": "Propranolol Hydrochloride",
"DosageFormName": "TABLET",
"RouteName": "ORAL",
"StartMarketingDate": "20110920",
"MarketingCategoryName": "ANDA",
"ApplicationNumber": "ANDA070213",
"LabelerName": "UDL Laboratories, Inc.",
"SubstanceName": "PROPRANOLOL HYDROCHLORIDE",
"StrengthNumber": "10",
"StrengthUnit": "mg/1",
"Pharm_Classes": "Adrenergic beta-Antagonists [MoA],beta-Adrenergic Blocker [EPC]",
"Status": "Deprecated",
"LastUpdate": "2015-04-10"
},
{
"NDCCode": "52584-277-01",
"PackageDescription": "1 VIAL, MULTI-DOSE in 1 BAG (52584-277-01) > 20 mL in 1 VIAL, MULTI-DOSE",
"NDC11Code": "52584-0277-01",
"ProductNDC": "52584-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Lidocaine Hydrochloride",
"NonProprietaryName": "Lidocaine Hydrochloride Anhydrous",
"DosageFormName": "INJECTION, SOLUTION",
"RouteName": "INFILTRATION; PERINEURAL",
"StartMarketingDate": "20100901",
"EndMarketingDate": "20240301",
"MarketingCategoryName": "ANDA",
"ApplicationNumber": "ANDA088327",
"LabelerName": "General Injectables & Vaccines, Inc",
"SubstanceName": "LIDOCAINE HYDROCHLORIDE",
"StrengthNumber": "20",
"StrengthUnit": "mg/mL",
"Pharm_Classes": "Amide Local Anesthetic [EPC], Amides [CS], Antiarrhythmic [EPC], Local Anesthesia [PE]",
"Status": "Deprecated",
"LastUpdate": "2023-01-03",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20100901",
"EndMarketingDatePackage": "20230101",
"SamplePackage": "N",
"IndicationAndUsage": "Lidocaine Hydrochloride Injection, USP is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.",
"Description": "Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution of lidocaine hydrochloride in water for injection for parenteral administration in various concentrations with characteristics as follows. Multiple-dose vials contain 0.1% of methylparaben added as preservative. May contain sodium hydroxide and/or hydrochloric acid for pH adjustment. The pH is 6.5 (5.0 to 7.0). See HOW SUPPLIED section for various sizes and strengths. Lidocaine is a local anesthetic of the amide type. Lidocaine Hydrochloride, USP is chemically designated 2-(diethylamino)-N-(2,6-dimethylphenyl)-acetamide monohydrochloride monohydrate, a white powder freely soluble in water. The molecular weight is 288.82. It has the following structural formula. The semi-rigid vial used for the plastic vials is fabricated from a specially formulated polyolefin. It is a copolymer of ethylene and propylene. The safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers. The container requires no vapor barrier to maintain the proper drug concentration."
},
{
"NDCCode": "57687-277-20",
"PackageDescription": "1 BOTTLE, DROPPER in 1 CARTON (57687-277-20) > 20 mL in 1 BOTTLE, DROPPER",
"NDC11Code": "57687-0277-20",
"ProductNDC": "57687-277",
"ProductTypeName": "HUMAN OTC DRUG",
"ProprietaryName": "Bach Original Flower Remedies",
"NonProprietaryName": "Scleranthus Annuus Whole",
"DosageFormName": "SOLUTION",
"RouteName": "ORAL",
"StartMarketingDate": "20020101",
"MarketingCategoryName": "UNAPPROVED HOMEOPATHIC",
"LabelerName": "Nelson Bach USA Limited",
"SubstanceName": "SCLERANTHUS ANNUUS WHOLE",
"StrengthNumber": "5",
"StrengthUnit": "[hp_X]/.095mL",
"Status": "Active",
"LastUpdate": "2020-06-24",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20261231",
"StartMarketingDatePackage": "20020101",
"SamplePackage": "N",
"IndicationAndUsage": "For relief of naturally occurring simple nervous tension."
},
{
"NDCCode": "67046-277-20",
"PackageDescription": "20 TABLET in 1 BLISTER PACK (67046-277-20)",
"NDC11Code": "67046-0277-20",
"ProductNDC": "67046-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Hydrochlorothiazide",
"NonProprietaryName": "Hydrochlorothiazide",
"DosageFormName": "TABLET",
"RouteName": "ORAL",
"StartMarketingDate": "20170928",
"MarketingCategoryName": "ANDA",
"ApplicationNumber": "ANDA040807",
"LabelerName": "Contract Pharmacy Services-PA",
"SubstanceName": "HYDROCHLOROTHIAZIDE",
"StrengthNumber": "25",
"StrengthUnit": "mg/1",
"Pharm_Classes": "Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [CS]",
"Status": "Deprecated",
"LastUpdate": "2022-01-04",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20211231",
"IndicationAndUsage": "Hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.",
"Description": "Hydrochlorothiazide is a diuretic and antihypertensive. It is the 3,4-dihydro derivative of chlorothiazide. It is chemically designated as 6-chloro-3,4-dihydro- 2H-1,2,4-benzothiadiazine- 7-sulfonamide 1,1-dioxide and has the following structural formula:. C 7H 8ClN 3O 4S 2 M.W. 297.74. Hydrochlorothiazide is a white, or practically white, crystalline powder which is slightly soluble in water, but freely soluble in sodium hydroxide solution. Each tablet for oral administration contains 12.5 mg, 25 mg and 50 mg hydrochlorothiazide, USP. In addition, each tablet contains the following inactive ingredients: corn starch, dibasic calcium phosphate, lactose monohydrate, magnesium stearate, pregelatinized starch, and sodium starch glycolate.Tablets of 12.5 mg and 25 mg strengths also contain FD&C yellow #6."
},
{
"NDCCode": "69452-277-20",
"PackageDescription": "100 TABLET in 1 BOTTLE (69452-277-20) ",
"NDC11Code": "69452-0277-20",
"ProductNDC": "69452-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Dexamethasone",
"NonProprietaryName": "Dexamethasone",
"DosageFormName": "TABLET",
"RouteName": "ORAL",
"StartMarketingDate": "20230801",
"MarketingCategoryName": "ANDA",
"ApplicationNumber": "ANDA217001",
"LabelerName": "Bionpharma Inc.,",
"SubstanceName": "DEXAMETHASONE",
"StrengthNumber": "4",
"StrengthUnit": "mg/1",
"Pharm_Classes": "Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC]",
"Status": "Active",
"LastUpdate": "2025-03-07",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20261231",
"StartMarketingDatePackage": "20230801",
"SamplePackage": "N",
"IndicationAndUsage": "Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous: Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.",
"Description": "Dexamethasone tablets, USP, for oral administration, are supplied as 4 mg, and 6 mg. Inactive ingredients are corn starch, D&C yellow 10 (4 mg), FD&C blue 1 (6 mg), lactose monohydrate, and magnesium stearate. The molecular weight for dexamethasone is 392.5 g/mol. It is designated chemically as 9-fluoro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione. The molecular formula is C 22H 29FO 5 and the structural formula is:. Dexamethasone, USP a synthetic adrenocortical steroid, is a white to almost-white, crystalline powder. It is stable in air. It is practically insoluble in water, very slightly soluble in ether, slightly soluble in methylene chloride and chloroform, and sparingly soluble in methanol, ethanol (96 %), acetone and 1,4 dioxane."
},
{
"NDCCode": "72789-277-20",
"PackageDescription": "20 CAPSULE in 1 BOTTLE, PLASTIC (72789-277-20) ",
"NDC11Code": "72789-0277-20",
"ProductNDC": "72789-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Doxycycline Hyclate",
"NonProprietaryName": "Doxycycline Hyclate",
"DosageFormName": "CAPSULE",
"RouteName": "ORAL",
"StartMarketingDate": "19860710",
"MarketingCategoryName": "ANDA",
"ApplicationNumber": "ANDA062676",
"LabelerName": "PD-Rx Pharmaceuticals, Inc.",
"SubstanceName": "DOXYCYCLINE HYCLATE",
"StrengthNumber": "100",
"StrengthUnit": "mg/1",
"Pharm_Classes": "Tetracycline-class Drug [EPC], Tetracyclines [CS]",
"Status": "Active",
"LastUpdate": "2026-07-21",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20271231",
"StartMarketingDatePackage": "20221118",
"SamplePackage": "N",
"IndicationAndUsage": "To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",
"Description": "Doxycycline hyclate is an antibacterial drug synthetically derived from oxytetracycline, and is available as doxycycline hyclate (doxycycline hydrochloride hemiethanolate hemihydrate) capsules and tablets for oral administration. The chemical designation of this light-yellow crystalline powder is alpha-6-deoxy-5-oxytetracycline. Doxycycline has a high degree of lipoid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form. Doxycycline hyclate has the following structural formula. Each capsule for oral administration contains doxycycline hyclate equivalent to 50 mg or 100 mg doxycycline (anhydrous). Inactive ingredients for capsules are: anhydrous lactose, croscarmellose sodium, FD&C Blue #1, gelatin, magnesium stearate, microcrystalline cellulose, and titanium dioxide. Each tablet for oral administration contains doxycycline hyclate equivalent to 100 mg doxycycline. Inactive ingredients for tablets are: lactose monohydrate, carnauba wax, croscarmellose sodium, D&C Yellow #10 aluminum lake, FD&C Red #40 aluminum lake, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, and titanium dioxide."
},
{
"NDCCode": "73069-277-51",
"PackageDescription": "1 VIAL, MULTI-DOSE in 1 BOX (73069-277-51) > 20 mL in 1 VIAL, MULTI-DOSE",
"NDC11Code": "73069-0277-51",
"ProductNDC": "73069-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Viatrexx-ki-ub",
"NonProprietaryName": "Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone",
"DosageFormName": "INJECTION",
"RouteName": "INTRAMUSCULAR; INTRAVENOUS; PARENTERAL; SUBCUTANEOUS",
"StartMarketingDate": "20190329",
"MarketingCategoryName": "UNAPPROVED DRUG OTHER",
"LabelerName": "VIATREXX BIO INCORPORATED",
"SubstanceName": "NITRIC ACID; SUCCINIC ACID; ESCHERICHIA COLI; BERBERIS VULGARIS ROOT; EQUISETUM HYEMALE; POTASSIUM NITRATE; BEEF KIDNEY; PORK KIDNEY; METHYL BLUE; ONONIS SPINOSA WHOLE; CLERODENDRANTHUS SPICATUS LEAF; CHONDRODENDRON TOMENTOSUM ROOT; PLANTAGO MAJOR; SMILAX ORNATA ROOT; SOLIDAGO VIRGAUREA FLOWERING TOP; BOS TAURUS URETER; SUS SCROFA URETER; BOS TAURUS URINARY BLADDER; SUS SCROFA URINARY BLADDER; PROTEUS INCONSTANS; HIERACIUM PILOSELLA WHOLE; QUINHYDRONE",
"StrengthNumber": "31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31",
"StrengthUnit": "[kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL",
"Pharm_Classes": "Melanin Synthesis Inhibitor [EPC],Melanin Synthesis Inhibitors [MoA],Depigmenting Activity [PE]",
"Status": "Deprecated",
"LastUpdate": "2021-01-01",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20201231",
"StartMarketingDatePackage": "20190506",
"SamplePackage": "N"
},
{
"NDCCode": "73069-277-52",
"PackageDescription": "3 VIAL, MULTI-DOSE in 1 BOX (73069-277-52) > 20 mL in 1 VIAL, MULTI-DOSE",
"NDC11Code": "73069-0277-52",
"ProductNDC": "73069-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Viatrexx-ki-ub",
"NonProprietaryName": "Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone",
"DosageFormName": "INJECTION",
"RouteName": "INTRAMUSCULAR; INTRAVENOUS; PARENTERAL; SUBCUTANEOUS",
"StartMarketingDate": "20190329",
"MarketingCategoryName": "UNAPPROVED DRUG OTHER",
"LabelerName": "VIATREXX BIO INCORPORATED",
"SubstanceName": "NITRIC ACID; SUCCINIC ACID; ESCHERICHIA COLI; BERBERIS VULGARIS ROOT; EQUISETUM HYEMALE; POTASSIUM NITRATE; BEEF KIDNEY; PORK KIDNEY; METHYL BLUE; ONONIS SPINOSA WHOLE; CLERODENDRANTHUS SPICATUS LEAF; CHONDRODENDRON TOMENTOSUM ROOT; PLANTAGO MAJOR; SMILAX ORNATA ROOT; SOLIDAGO VIRGAUREA FLOWERING TOP; BOS TAURUS URETER; SUS SCROFA URETER; BOS TAURUS URINARY BLADDER; SUS SCROFA URINARY BLADDER; PROTEUS INCONSTANS; HIERACIUM PILOSELLA WHOLE; QUINHYDRONE",
"StrengthNumber": "31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31",
"StrengthUnit": "[kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL",
"Pharm_Classes": "Melanin Synthesis Inhibitor [EPC],Melanin Synthesis Inhibitors [MoA],Depigmenting Activity [PE]",
"Status": "Deprecated",
"LastUpdate": "2021-01-01",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20201231",
"StartMarketingDatePackage": "20190506",
"SamplePackage": "N"
},
{
"NDCCode": "73069-277-53",
"PackageDescription": "5 VIAL, MULTI-DOSE in 1 BOX (73069-277-53) > 20 mL in 1 VIAL, MULTI-DOSE",
"NDC11Code": "73069-0277-53",
"ProductNDC": "73069-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Viatrexx-ki-ub",
"NonProprietaryName": "Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone",
"DosageFormName": "INJECTION",
"RouteName": "INTRAMUSCULAR; INTRAVENOUS; PARENTERAL; SUBCUTANEOUS",
"StartMarketingDate": "20190329",
"MarketingCategoryName": "UNAPPROVED DRUG OTHER",
"LabelerName": "VIATREXX BIO INCORPORATED",
"SubstanceName": "NITRIC ACID; SUCCINIC ACID; ESCHERICHIA COLI; BERBERIS VULGARIS ROOT; EQUISETUM HYEMALE; POTASSIUM NITRATE; BEEF KIDNEY; PORK KIDNEY; METHYL BLUE; ONONIS SPINOSA WHOLE; CLERODENDRANTHUS SPICATUS LEAF; CHONDRODENDRON TOMENTOSUM ROOT; PLANTAGO MAJOR; SMILAX ORNATA ROOT; SOLIDAGO VIRGAUREA FLOWERING TOP; BOS TAURUS URETER; SUS SCROFA URETER; BOS TAURUS URINARY BLADDER; SUS SCROFA URINARY BLADDER; PROTEUS INCONSTANS; HIERACIUM PILOSELLA WHOLE; QUINHYDRONE",
"StrengthNumber": "31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31",
"StrengthUnit": "[kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL",
"Pharm_Classes": "Melanin Synthesis Inhibitor [EPC],Melanin Synthesis Inhibitors [MoA],Depigmenting Activity [PE]",
"Status": "Deprecated",
"LastUpdate": "2021-01-01",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20201231",
"StartMarketingDatePackage": "20190506",
"SamplePackage": "N"
},
{
"NDCCode": "73069-277-54",
"PackageDescription": "6 VIAL, MULTI-DOSE in 1 BOX (73069-277-54) > 20 mL in 1 VIAL, MULTI-DOSE",
"NDC11Code": "73069-0277-54",
"ProductNDC": "73069-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Viatrexx-ki-ub",
"NonProprietaryName": "Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone",
"DosageFormName": "INJECTION",
"RouteName": "INTRAMUSCULAR; INTRAVENOUS; PARENTERAL; SUBCUTANEOUS",
"StartMarketingDate": "20190329",
"MarketingCategoryName": "UNAPPROVED DRUG OTHER",
"LabelerName": "VIATREXX BIO INCORPORATED",
"SubstanceName": "NITRIC ACID; SUCCINIC ACID; ESCHERICHIA COLI; BERBERIS VULGARIS ROOT; EQUISETUM HYEMALE; POTASSIUM NITRATE; BEEF KIDNEY; PORK KIDNEY; METHYL BLUE; ONONIS SPINOSA WHOLE; CLERODENDRANTHUS SPICATUS LEAF; CHONDRODENDRON TOMENTOSUM ROOT; PLANTAGO MAJOR; SMILAX ORNATA ROOT; SOLIDAGO VIRGAUREA FLOWERING TOP; BOS TAURUS URETER; SUS SCROFA URETER; BOS TAURUS URINARY BLADDER; SUS SCROFA URINARY BLADDER; PROTEUS INCONSTANS; HIERACIUM PILOSELLA WHOLE; QUINHYDRONE",
"StrengthNumber": "31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31",
"StrengthUnit": "[kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL",
"Pharm_Classes": "Melanin Synthesis Inhibitor [EPC],Melanin Synthesis Inhibitors [MoA],Depigmenting Activity [PE]",
"Status": "Deprecated",
"LastUpdate": "2021-01-01",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20201231",
"StartMarketingDatePackage": "20190506",
"SamplePackage": "N"
},
{
"NDCCode": "73069-277-55",
"PackageDescription": "10 VIAL, MULTI-DOSE in 1 BOX (73069-277-55) > 20 mL in 1 VIAL, MULTI-DOSE",
"NDC11Code": "73069-0277-55",
"ProductNDC": "73069-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Viatrexx-ki-ub",
"NonProprietaryName": "Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone",
"DosageFormName": "INJECTION",
"RouteName": "INTRAMUSCULAR; INTRAVENOUS; PARENTERAL; SUBCUTANEOUS",
"StartMarketingDate": "20190329",
"MarketingCategoryName": "UNAPPROVED DRUG OTHER",
"LabelerName": "VIATREXX BIO INCORPORATED",
"SubstanceName": "NITRIC ACID; SUCCINIC ACID; ESCHERICHIA COLI; BERBERIS VULGARIS ROOT; EQUISETUM HYEMALE; POTASSIUM NITRATE; BEEF KIDNEY; PORK KIDNEY; METHYL BLUE; ONONIS SPINOSA WHOLE; CLERODENDRANTHUS SPICATUS LEAF; CHONDRODENDRON TOMENTOSUM ROOT; PLANTAGO MAJOR; SMILAX ORNATA ROOT; SOLIDAGO VIRGAUREA FLOWERING TOP; BOS TAURUS URETER; SUS SCROFA URETER; BOS TAURUS URINARY BLADDER; SUS SCROFA URINARY BLADDER; PROTEUS INCONSTANS; HIERACIUM PILOSELLA WHOLE; QUINHYDRONE",
"StrengthNumber": "31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31",
"StrengthUnit": "[kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL",
"Pharm_Classes": "Melanin Synthesis Inhibitor [EPC],Melanin Synthesis Inhibitors [MoA],Depigmenting Activity [PE]",
"Status": "Deprecated",
"LastUpdate": "2021-01-01",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20201231",
"StartMarketingDatePackage": "20190506",
"SamplePackage": "N"
},
{
"NDCCode": "73069-277-56",
"PackageDescription": "12 VIAL, MULTI-DOSE in 1 BOX (73069-277-56) > 20 mL in 1 VIAL, MULTI-DOSE",
"NDC11Code": "73069-0277-56",
"ProductNDC": "73069-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Viatrexx-ki-ub",
"NonProprietaryName": "Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone",
"DosageFormName": "INJECTION",
"RouteName": "INTRAMUSCULAR; INTRAVENOUS; PARENTERAL; SUBCUTANEOUS",
"StartMarketingDate": "20190329",
"MarketingCategoryName": "UNAPPROVED DRUG OTHER",
"LabelerName": "VIATREXX BIO INCORPORATED",
"SubstanceName": "NITRIC ACID; SUCCINIC ACID; ESCHERICHIA COLI; BERBERIS VULGARIS ROOT; EQUISETUM HYEMALE; POTASSIUM NITRATE; BEEF KIDNEY; PORK KIDNEY; METHYL BLUE; ONONIS SPINOSA WHOLE; CLERODENDRANTHUS SPICATUS LEAF; CHONDRODENDRON TOMENTOSUM ROOT; PLANTAGO MAJOR; SMILAX ORNATA ROOT; SOLIDAGO VIRGAUREA FLOWERING TOP; BOS TAURUS URETER; SUS SCROFA URETER; BOS TAURUS URINARY BLADDER; SUS SCROFA URINARY BLADDER; PROTEUS INCONSTANS; HIERACIUM PILOSELLA WHOLE; QUINHYDRONE",
"StrengthNumber": "31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31",
"StrengthUnit": "[kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL",
"Pharm_Classes": "Melanin Synthesis Inhibitor [EPC],Melanin Synthesis Inhibitors [MoA],Depigmenting Activity [PE]",
"Status": "Deprecated",
"LastUpdate": "2021-01-01",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20201231",
"StartMarketingDatePackage": "20190506",
"SamplePackage": "N"
},
{
"NDCCode": "73069-277-57",
"PackageDescription": "25 VIAL, MULTI-DOSE in 1 BOX (73069-277-57) > 20 mL in 1 VIAL, MULTI-DOSE",
"NDC11Code": "73069-0277-57",
"ProductNDC": "73069-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Viatrexx-ki-ub",
"NonProprietaryName": "Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone",
"DosageFormName": "INJECTION",
"RouteName": "INTRAMUSCULAR; INTRAVENOUS; PARENTERAL; SUBCUTANEOUS",
"StartMarketingDate": "20190329",
"MarketingCategoryName": "UNAPPROVED DRUG OTHER",
"LabelerName": "VIATREXX BIO INCORPORATED",
"SubstanceName": "NITRIC ACID; SUCCINIC ACID; ESCHERICHIA COLI; BERBERIS VULGARIS ROOT; EQUISETUM HYEMALE; POTASSIUM NITRATE; BEEF KIDNEY; PORK KIDNEY; METHYL BLUE; ONONIS SPINOSA WHOLE; CLERODENDRANTHUS SPICATUS LEAF; CHONDRODENDRON TOMENTOSUM ROOT; PLANTAGO MAJOR; SMILAX ORNATA ROOT; SOLIDAGO VIRGAUREA FLOWERING TOP; BOS TAURUS URETER; SUS SCROFA URETER; BOS TAURUS URINARY BLADDER; SUS SCROFA URINARY BLADDER; PROTEUS INCONSTANS; HIERACIUM PILOSELLA WHOLE; QUINHYDRONE",
"StrengthNumber": "31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31",
"StrengthUnit": "[kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL",
"Pharm_Classes": "Melanin Synthesis Inhibitor [EPC],Melanin Synthesis Inhibitors [MoA],Depigmenting Activity [PE]",
"Status": "Deprecated",
"LastUpdate": "2021-01-01",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20201231",
"StartMarketingDatePackage": "20190506",
"SamplePackage": "N"
},
{
"NDCCode": "73069-277-58",
"PackageDescription": "50 VIAL, MULTI-DOSE in 1 BOX (73069-277-58) > 20 mL in 1 VIAL, MULTI-DOSE",
"NDC11Code": "73069-0277-58",
"ProductNDC": "73069-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Viatrexx-ki-ub",
"NonProprietaryName": "Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone",
"DosageFormName": "INJECTION",
"RouteName": "INTRAMUSCULAR; INTRAVENOUS; PARENTERAL; SUBCUTANEOUS",
"StartMarketingDate": "20190329",
"MarketingCategoryName": "UNAPPROVED DRUG OTHER",
"LabelerName": "VIATREXX BIO INCORPORATED",
"SubstanceName": "NITRIC ACID; SUCCINIC ACID; ESCHERICHIA COLI; BERBERIS VULGARIS ROOT; EQUISETUM HYEMALE; POTASSIUM NITRATE; BEEF KIDNEY; PORK KIDNEY; METHYL BLUE; ONONIS SPINOSA WHOLE; CLERODENDRANTHUS SPICATUS LEAF; CHONDRODENDRON TOMENTOSUM ROOT; PLANTAGO MAJOR; SMILAX ORNATA ROOT; SOLIDAGO VIRGAUREA FLOWERING TOP; BOS TAURUS URETER; SUS SCROFA URETER; BOS TAURUS URINARY BLADDER; SUS SCROFA URINARY BLADDER; PROTEUS INCONSTANS; HIERACIUM PILOSELLA WHOLE; QUINHYDRONE",
"StrengthNumber": "31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31",
"StrengthUnit": "[kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL",
"Pharm_Classes": "Melanin Synthesis Inhibitor [EPC],Melanin Synthesis Inhibitors [MoA],Depigmenting Activity [PE]",
"Status": "Deprecated",
"LastUpdate": "2021-01-01",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20201231",
"StartMarketingDatePackage": "20190506",
"SamplePackage": "N"
},
{
"NDCCode": "73069-277-59",
"PackageDescription": "100 VIAL, MULTI-DOSE in 1 BOX (73069-277-59) > 20 mL in 1 VIAL, MULTI-DOSE",
"NDC11Code": "73069-0277-59",
"ProductNDC": "73069-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Viatrexx-ki-ub",
"NonProprietaryName": "Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone",
"DosageFormName": "INJECTION",
"RouteName": "INTRAMUSCULAR; INTRAVENOUS; PARENTERAL; SUBCUTANEOUS",
"StartMarketingDate": "20190329",
"MarketingCategoryName": "UNAPPROVED DRUG OTHER",
"LabelerName": "VIATREXX BIO INCORPORATED",
"SubstanceName": "NITRIC ACID; SUCCINIC ACID; ESCHERICHIA COLI; BERBERIS VULGARIS ROOT; EQUISETUM HYEMALE; POTASSIUM NITRATE; BEEF KIDNEY; PORK KIDNEY; METHYL BLUE; ONONIS SPINOSA WHOLE; CLERODENDRANTHUS SPICATUS LEAF; CHONDRODENDRON TOMENTOSUM ROOT; PLANTAGO MAJOR; SMILAX ORNATA ROOT; SOLIDAGO VIRGAUREA FLOWERING TOP; BOS TAURUS URETER; SUS SCROFA URETER; BOS TAURUS URINARY BLADDER; SUS SCROFA URINARY BLADDER; PROTEUS INCONSTANS; HIERACIUM PILOSELLA WHOLE; QUINHYDRONE",
"StrengthNumber": "31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31",
"StrengthUnit": "[kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL",
"Pharm_Classes": "Melanin Synthesis Inhibitor [EPC],Melanin Synthesis Inhibitors [MoA],Depigmenting Activity [PE]",
"Status": "Deprecated",
"LastUpdate": "2021-01-01",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20201231",
"StartMarketingDatePackage": "20190506",
"SamplePackage": "N"
},
{
"NDCCode": "10702-277-03",
"PackageDescription": "30 TABLET in 1 BOTTLE (10702-277-03) ",
"NDC11Code": "10702-0277-03",
"ProductNDC": "10702-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Leflunomide",
"NonProprietaryName": "Leflunomide",
"DosageFormName": "TABLET",
"RouteName": "ORAL",
"StartMarketingDate": "20200723",
"MarketingCategoryName": "ANDA",
"ApplicationNumber": "ANDA212453",
"LabelerName": "KVK-Tech, Inc.",
"SubstanceName": "LEFLUNOMIDE",
"StrengthNumber": "10",
"StrengthUnit": "mg/1",
"Pharm_Classes": "Antirheumatic Agent [EPC]",
"Status": "Active",
"LastUpdate": "2025-06-25",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"ListingRecordCertifiedThrough": "20261231",
"StartMarketingDatePackage": "20200723",
"SamplePackage": "N",
"IndicationAndUsage": "Leflunomide tablets are indicated for the treatment of adults with active rheumatoid arthritis (RA).",
"Description": "Leflunomide is a pyrimidine synthesis inhibitor. The chemical name for leflunomide is 4-Isoxazolecarboxamide, 5-methyl-N-[4-(trifluoromethyl)-phenyl]-. It has an empirical formula C12H9F3N2O2, a molecular weight of 270.21 and the following structural formula. Leflunomide tablets are available for oral administration as film coated tablets containing 10, or 20 mg of active drug. Combined with leflunomide are the following inactive ingredients: colloidal silicon dioxide, crospovidone, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, povidone, corn starch, talc, titanium dioxide, and yellow ferric oxide (20 mg tablet only)."
},
{
"NDCCode": "21695-277-15",
"PackageDescription": "15 CAPSULE in 1 BOTTLE (21695-277-15)",
"NDC11Code": "21695-0277-15",
"ProductNDC": "21695-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Lyrica",
"NonProprietaryName": "Pregabalin",
"DosageFormName": "CAPSULE",
"RouteName": "ORAL",
"StartMarketingDate": "20050610",
"MarketingCategoryName": "NDA",
"ApplicationNumber": "NDA021724",
"LabelerName": "Rebel Distributors Corp",
"SubstanceName": "PREGABALIN",
"StrengthNumber": "50",
"StrengthUnit": "mg/1",
"DEASchedule": "CV",
"Status": "Deprecated",
"LastUpdate": "2019-09-21",
"ProductNdcExcludeFlag": "E",
"ListingRecordCertifiedThrough": "20171231",
"IndicationAndUsage": "LYRICA is indicated for.",
"Description": "Pregabalin is described chemically as (S)-3-(aminomethyl)-5-methylhexanoic acid. The molecular formula is C8H17NO2 and the molecular weight is 159.23. The chemical structure of pregabalin is. Pregabalin is a white to off-white, crystalline solid with a pKa1 of 4.2 and a pKa2 of 10.6. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05M phosphate buffer) at pH 7.4 is – 1.35. LYRICA (pregabalin) Capsules are administered orally and are supplied as imprinted hard-shell capsules containing 25, 50, 75, 100, 150, 200, 225, and 300 mg of pregabalin, along with lactose monohydrate, cornstarch, and talc as inactive ingredients. The capsule shells contain gelatin and titanium dioxide. In addition, the orange capsule shells contain red iron oxide and the white capsule shells contain sodium lauryl sulfate and colloidal silicon dioxide. Colloidal silicon dioxide is a manufacturing aid that may or may not be present in the capsule shells. The imprinting ink contains shellac, black iron oxide, propylene glycol, and potassium hydroxide. LYRICA (pregabalin) oral solution, 20 mg/mL, is administered orally and is supplied as a clear, colorless solution contained in a 16 fluid ounce white HDPE bottle with a polyethylene-lined closure. The oral solution contains 20 mg/mL of pregabalin, along with methylparaben, propylparaben, monobasic sodium phosphate anhydrous, dibasic sodium phosphate anhydrous, sucralose, artificial strawberry #11545 and purified water as inactive ingredients."
},
{
"NDCCode": "21695-277-30",
"PackageDescription": "30 CAPSULE in 1 BOTTLE (21695-277-30)",
"NDC11Code": "21695-0277-30",
"ProductNDC": "21695-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Lyrica",
"NonProprietaryName": "Pregabalin",
"DosageFormName": "CAPSULE",
"RouteName": "ORAL",
"StartMarketingDate": "20050610",
"MarketingCategoryName": "NDA",
"ApplicationNumber": "NDA021724",
"LabelerName": "Rebel Distributors Corp",
"SubstanceName": "PREGABALIN",
"StrengthNumber": "50",
"StrengthUnit": "mg/1",
"DEASchedule": "CV",
"Status": "Deprecated",
"LastUpdate": "2019-09-21",
"ProductNdcExcludeFlag": "E",
"ListingRecordCertifiedThrough": "20171231",
"IndicationAndUsage": "LYRICA is indicated for.",
"Description": "Pregabalin is described chemically as (S)-3-(aminomethyl)-5-methylhexanoic acid. The molecular formula is C8H17NO2 and the molecular weight is 159.23. The chemical structure of pregabalin is. Pregabalin is a white to off-white, crystalline solid with a pKa1 of 4.2 and a pKa2 of 10.6. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05M phosphate buffer) at pH 7.4 is – 1.35. LYRICA (pregabalin) Capsules are administered orally and are supplied as imprinted hard-shell capsules containing 25, 50, 75, 100, 150, 200, 225, and 300 mg of pregabalin, along with lactose monohydrate, cornstarch, and talc as inactive ingredients. The capsule shells contain gelatin and titanium dioxide. In addition, the orange capsule shells contain red iron oxide and the white capsule shells contain sodium lauryl sulfate and colloidal silicon dioxide. Colloidal silicon dioxide is a manufacturing aid that may or may not be present in the capsule shells. The imprinting ink contains shellac, black iron oxide, propylene glycol, and potassium hydroxide. LYRICA (pregabalin) oral solution, 20 mg/mL, is administered orally and is supplied as a clear, colorless solution contained in a 16 fluid ounce white HDPE bottle with a polyethylene-lined closure. The oral solution contains 20 mg/mL of pregabalin, along with methylparaben, propylparaben, monobasic sodium phosphate anhydrous, dibasic sodium phosphate anhydrous, sucralose, artificial strawberry #11545 and purified water as inactive ingredients."
},
{
"NDCCode": "21695-277-90",
"PackageDescription": "90 CAPSULE in 1 BOTTLE (21695-277-90)",
"NDC11Code": "21695-0277-90",
"ProductNDC": "21695-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Lyrica",
"NonProprietaryName": "Pregabalin",
"DosageFormName": "CAPSULE",
"RouteName": "ORAL",
"StartMarketingDate": "20050610",
"MarketingCategoryName": "NDA",
"ApplicationNumber": "NDA021724",
"LabelerName": "Rebel Distributors Corp",
"SubstanceName": "PREGABALIN",
"StrengthNumber": "50",
"StrengthUnit": "mg/1",
"DEASchedule": "CV",
"Status": "Deprecated",
"LastUpdate": "2019-09-21",
"ProductNdcExcludeFlag": "E",
"ListingRecordCertifiedThrough": "20171231",
"IndicationAndUsage": "LYRICA is indicated for.",
"Description": "Pregabalin is described chemically as (S)-3-(aminomethyl)-5-methylhexanoic acid. The molecular formula is C8H17NO2 and the molecular weight is 159.23. The chemical structure of pregabalin is. Pregabalin is a white to off-white, crystalline solid with a pKa1 of 4.2 and a pKa2 of 10.6. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05M phosphate buffer) at pH 7.4 is – 1.35. LYRICA (pregabalin) Capsules are administered orally and are supplied as imprinted hard-shell capsules containing 25, 50, 75, 100, 150, 200, 225, and 300 mg of pregabalin, along with lactose monohydrate, cornstarch, and talc as inactive ingredients. The capsule shells contain gelatin and titanium dioxide. In addition, the orange capsule shells contain red iron oxide and the white capsule shells contain sodium lauryl sulfate and colloidal silicon dioxide. Colloidal silicon dioxide is a manufacturing aid that may or may not be present in the capsule shells. The imprinting ink contains shellac, black iron oxide, propylene glycol, and potassium hydroxide. LYRICA (pregabalin) oral solution, 20 mg/mL, is administered orally and is supplied as a clear, colorless solution contained in a 16 fluid ounce white HDPE bottle with a polyethylene-lined closure. The oral solution contains 20 mg/mL of pregabalin, along with methylparaben, propylparaben, monobasic sodium phosphate anhydrous, dibasic sodium phosphate anhydrous, sucralose, artificial strawberry #11545 and purified water as inactive ingredients."
},
{
"NDCCode": "27808-277-01",
"PackageDescription": "30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (27808-277-01) ",
"NDC11Code": "27808-0277-01",
"ProductNDC": "27808-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Olmesartan Medoxomil",
"NonProprietaryName": "Olmesartan Medoxomil",
"DosageFormName": "TABLET, FILM COATED",
"RouteName": "ORAL",
"StartMarketingDate": "20230520",
"EndMarketingDate": "20250131",
"MarketingCategoryName": "ANDA",
"ApplicationNumber": "ANDA210552",
"LabelerName": "Tris Pharma, Inc.",
"SubstanceName": "OLMESARTAN MEDOXOMIL",
"StrengthNumber": "40",
"StrengthUnit": "mg/1",
"Pharm_Classes": "Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC]",
"Status": "Deprecated",
"LastUpdate": "2025-02-04",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20230520",
"EndMarketingDatePackage": "20250131",
"SamplePackage": "N",
"IndicationAndUsage": "Olmesartan Medoxomil Tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Olmesartan Medoxomil Tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents.",
"Description": "Olmesartan medoxomil, a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. Olmesartan is a selective AT 1subtype angiotensin II receptor antagonist. Olmesartan medoxomil is described chemically as 2,3-dihydroxy-2-butenyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[ p-( o-1 H-tetrazol-5-ylphenyl)benzyl]imidazole-5-carboxylate, cyclic 2,3-carbonate. Its empirical formula is C 29H 30N 6O 6and its structural formula is:. Olmesartan medoxomil, USP is a white to light yellowish-white powder or crystalline powder with a molecular weight of 558.59. It is practically insoluble in water and sparingly soluble in methanol. Olmesartan Medoxomil Tablets, USP are available for oral use as film-coated tablets containing 5 mg, 20 mg, or 40 mg of olmesartan medoxomil and the following inactive ingredients: hydroxypropyl cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, hypromellose, talc, titanium dioxide, and (5 mg only) yellow iron oxide. Meets USP dissolution test 7."
},
{
"NDCCode": "27808-277-02",
"PackageDescription": "90 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (27808-277-02) ",
"NDC11Code": "27808-0277-02",
"ProductNDC": "27808-277",
"ProductTypeName": "HUMAN PRESCRIPTION DRUG",
"ProprietaryName": "Olmesartan Medoxomil",
"NonProprietaryName": "Olmesartan Medoxomil",
"DosageFormName": "TABLET, FILM COATED",
"RouteName": "ORAL",
"StartMarketingDate": "20230520",
"EndMarketingDate": "20250131",
"MarketingCategoryName": "ANDA",
"ApplicationNumber": "ANDA210552",
"LabelerName": "Tris Pharma, Inc.",
"SubstanceName": "OLMESARTAN MEDOXOMIL",
"StrengthNumber": "40",
"StrengthUnit": "mg/1",
"Pharm_Classes": "Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC]",
"Status": "Deprecated",
"LastUpdate": "2025-02-04",
"PackageNdcExcludeFlag": "N",
"ProductNdcExcludeFlag": "N",
"StartMarketingDatePackage": "20230520",
"EndMarketingDatePackage": "20250131",
"SamplePackage": "N",
"IndicationAndUsage": "Olmesartan Medoxomil Tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Olmesartan Medoxomil Tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents.",
"Description": "Olmesartan medoxomil, a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. Olmesartan is a selective AT 1subtype angiotensin II receptor antagonist. Olmesartan medoxomil is described chemically as 2,3-dihydroxy-2-butenyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[ p-( o-1 H-tetrazol-5-ylphenyl)benzyl]imidazole-5-carboxylate, cyclic 2,3-carbonate. Its empirical formula is C 29H 30N 6O 6and its structural formula is:. Olmesartan medoxomil, USP is a white to light yellowish-white powder or crystalline powder with a molecular weight of 558.59. It is practically insoluble in water and sparingly soluble in methanol. Olmesartan Medoxomil Tablets, USP are available for oral use as film-coated tablets containing 5 mg, 20 mg, or 40 mg of olmesartan medoxomil and the following inactive ingredients: hydroxypropyl cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, hypromellose, talc, titanium dioxide, and (5 mg only) yellow iron oxide. Meets USP dissolution test 7."
}
]
}
{"NDC":[{"NDCCode":"76233-277-20","ProprietaryName":"Piperacillin And Tazobactam","NonProprietaryName":"Piperacillin And Tazobactam"},{"NDCCode":"76233-091-01","ProprietaryName":"Daptomycin","NonProprietaryName":"Daptomycin"},{"NDCCode":"76233-091-05","ProprietaryName":"Daptomycin","NonProprietaryName":"Daptomycin"},{"NDCCode":"76233-278-20","ProprietaryName":"Piperacillin And Tazobactam","NonProprietaryName":"Piperacillin And Tazobactam"},{"NDCCode":"76233-279-20","ProprietaryName":"Piperacillin And Tazobactam","NonProprietaryName":"Piperacillin And Tazobactam"},{"NDCCode":"10544-277-20","ProprietaryName":"Naproxen","NonProprietaryName":"Naproxen"},{"NDCCode":"43744-277-20","NonProprietaryName":"Diclofenac Sodium"},{"NDCCode":"43744-277-22","NonProprietaryName":"Diclofenac Sodium"},{"NDCCode":"49999-277-20","ProprietaryName":"Hydrocodone Bitartrate And Acetaminophen","NonProprietaryName":"Hydrocodone Bitartrate And Acetaminophen"},{"NDCCode":"51079-277-20","ProprietaryName":"Propranolol Hydrochloride","NonProprietaryName":"Propranolol Hydrochloride"},{"NDCCode":"52584-277-01","ProprietaryName":"Lidocaine Hydrochloride","NonProprietaryName":"Lidocaine Hydrochloride Anhydrous"},{"NDCCode":"57687-277-20","ProprietaryName":"Bach Original Flower Remedies","NonProprietaryName":"Scleranthus Annuus Whole"},{"NDCCode":"67046-277-20","ProprietaryName":"Hydrochlorothiazide","NonProprietaryName":"Hydrochlorothiazide"},{"NDCCode":"69452-277-20","ProprietaryName":"Dexamethasone","NonProprietaryName":"Dexamethasone"},{"NDCCode":"72789-277-20","ProprietaryName":"Doxycycline Hyclate","NonProprietaryName":"Doxycycline Hyclate"},{"NDCCode":"73069-277-51","ProprietaryName":"Viatrexx-ki-ub","NonProprietaryName":"Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone"},{"NDCCode":"73069-277-52","ProprietaryName":"Viatrexx-ki-ub","NonProprietaryName":"Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone"},{"NDCCode":"73069-277-53","ProprietaryName":"Viatrexx-ki-ub","NonProprietaryName":"Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone"},{"NDCCode":"73069-277-54","ProprietaryName":"Viatrexx-ki-ub","NonProprietaryName":"Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone"},{"NDCCode":"73069-277-55","ProprietaryName":"Viatrexx-ki-ub","NonProprietaryName":"Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone"},{"NDCCode":"73069-277-56","ProprietaryName":"Viatrexx-ki-ub","NonProprietaryName":"Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone"},{"NDCCode":"73069-277-57","ProprietaryName":"Viatrexx-ki-ub","NonProprietaryName":"Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone"},{"NDCCode":"73069-277-58","ProprietaryName":"Viatrexx-ki-ub","NonProprietaryName":"Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone"},{"NDCCode":"73069-277-59","ProprietaryName":"Viatrexx-ki-ub","NonProprietaryName":"Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone"},{"NDCCode":"10702-277-03","ProprietaryName":"Leflunomide","NonProprietaryName":"Leflunomide"},{"NDCCode":"21695-277-15","ProprietaryName":"Lyrica","NonProprietaryName":"Pregabalin"},{"NDCCode":"21695-277-30","ProprietaryName":"Lyrica","NonProprietaryName":"Pregabalin"},{"NDCCode":"21695-277-90","ProprietaryName":"Lyrica","NonProprietaryName":"Pregabalin"},{"NDCCode":"27808-277-01","ProprietaryName":"Olmesartan Medoxomil","NonProprietaryName":"Olmesartan Medoxomil"},{"NDCCode":"27808-277-02","ProprietaryName":"Olmesartan Medoxomil","NonProprietaryName":"Olmesartan Medoxomil"}]}
<?xml version="1.0" encoding="utf-8"?>
<NDCList>
<NDC>
<NDCCode>76233-277-20</NDCCode>
<PackageDescription>10 VIAL, SINGLE-DOSE in 1 CARTON (76233-277-20) > 15 mL in 1 VIAL, SINGLE-DOSE (76233-277-00) </PackageDescription>
<NDC11Code>76233-0277-20</NDC11Code>
<ProductNDC>76233-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Piperacillin And Tazobactam</ProprietaryName>
<NonProprietaryName>Piperacillin And Tazobactam</NonProprietaryName>
<DosageFormName>INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION</DosageFormName>
<RouteName>INTRAVENOUS</RouteName>
<StartMarketingDate>20200724</StartMarketingDate>
<MarketingCategoryName>ANDA</MarketingCategoryName>
<ApplicationNumber>ANDA203768</ApplicationNumber>
<LabelerName>Laboratorio Reig Jofre Sa.</LabelerName>
<SubstanceName>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM</SubstanceName>
<StrengthNumber>3; .375</StrengthNumber>
<StrengthUnit>g/15mL; g/15mL</StrengthUnit>
<Pharm_Classes>Penicillin-class Antibacterial [EPC],Penicillins [CS],beta Lactamase Inhibitors [MoA],beta Lactamase Inhibitor [EPC]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2021-07-28</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20211231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20200724</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>76233-091-01</NDCCode>
<PackageDescription>1 VIAL, SINGLE-USE in 1 CARTON (76233-091-01) > 20 mL in 1 VIAL, SINGLE-USE</PackageDescription>
<NDC11Code>76233-0091-01</NDC11Code>
<ProductNDC>76233-091</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Daptomycin</ProprietaryName>
<NonProprietaryName>Daptomycin</NonProprietaryName>
<DosageFormName>INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION</DosageFormName>
<RouteName>INTRAVENOUS</RouteName>
<StartMarketingDate>20210203</StartMarketingDate>
<MarketingCategoryName>ANDA</MarketingCategoryName>
<ApplicationNumber>ANDA210057</ApplicationNumber>
<LabelerName>Laboratorio Reig Jofre, S.A.</LabelerName>
<SubstanceName>DAPTOMYCIN</SubstanceName>
<StrengthNumber>500</StrengthNumber>
<StrengthUnit>mg/10mL</StrengthUnit>
<Pharm_Classes>Lipopeptide Antibacterial [EPC],Lipopeptides [CS]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2021-08-24</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20211231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20210203</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>76233-091-05</NDCCode>
<PackageDescription>5 VIAL, SINGLE-USE in 1 CARTON (76233-091-05) > 20 mL in 1 VIAL, SINGLE-USE</PackageDescription>
<NDC11Code>76233-0091-05</NDC11Code>
<ProductNDC>76233-091</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Daptomycin</ProprietaryName>
<NonProprietaryName>Daptomycin</NonProprietaryName>
<DosageFormName>INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION</DosageFormName>
<RouteName>INTRAVENOUS</RouteName>
<StartMarketingDate>20210203</StartMarketingDate>
<MarketingCategoryName>ANDA</MarketingCategoryName>
<ApplicationNumber>ANDA210057</ApplicationNumber>
<LabelerName>Laboratorio Reig Jofre, S.A.</LabelerName>
<SubstanceName>DAPTOMYCIN</SubstanceName>
<StrengthNumber>500</StrengthNumber>
<StrengthUnit>mg/10mL</StrengthUnit>
<Pharm_Classes>Lipopeptide Antibacterial [EPC],Lipopeptides [CS]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2021-08-24</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20211231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20210203</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>76233-278-20</NDCCode>
<PackageDescription>10 VIAL, SINGLE-DOSE in 1 CARTON (76233-278-20) > 20 mL in 1 VIAL, SINGLE-DOSE (76233-278-00) </PackageDescription>
<NDC11Code>76233-0278-20</NDC11Code>
<ProductNDC>76233-278</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Piperacillin And Tazobactam</ProprietaryName>
<NonProprietaryName>Piperacillin And Tazobactam</NonProprietaryName>
<DosageFormName>INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION</DosageFormName>
<RouteName>INTRAVENOUS</RouteName>
<StartMarketingDate>20200724</StartMarketingDate>
<MarketingCategoryName>ANDA</MarketingCategoryName>
<ApplicationNumber>ANDA203768</ApplicationNumber>
<LabelerName>Laboratorio Reig Jofre Sa.</LabelerName>
<SubstanceName>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM</SubstanceName>
<StrengthNumber>4; .5</StrengthNumber>
<StrengthUnit>g/20mL; g/20mL</StrengthUnit>
<Pharm_Classes>Penicillin-class Antibacterial [EPC],Penicillins [CS],beta Lactamase Inhibitors [MoA],beta Lactamase Inhibitor [EPC]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2021-07-28</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20211231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20200724</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>76233-279-20</NDCCode>
<PackageDescription>10 VIAL, SINGLE-DOSE in 1 CARTON (76233-279-20) > 10 mL in 1 VIAL, SINGLE-DOSE (76233-279-00) </PackageDescription>
<NDC11Code>76233-0279-20</NDC11Code>
<ProductNDC>76233-279</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Piperacillin And Tazobactam</ProprietaryName>
<NonProprietaryName>Piperacillin And Tazobactam</NonProprietaryName>
<DosageFormName>INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION</DosageFormName>
<RouteName>INTRAVENOUS</RouteName>
<StartMarketingDate>20200724</StartMarketingDate>
<MarketingCategoryName>ANDA</MarketingCategoryName>
<ApplicationNumber>ANDA203768</ApplicationNumber>
<LabelerName>Laboratorio Reig Jofre Sa.</LabelerName>
<SubstanceName>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM</SubstanceName>
<StrengthNumber>2; .25</StrengthNumber>
<StrengthUnit>g/10mL; g/10mL</StrengthUnit>
<Pharm_Classes>Penicillin-class Antibacterial [EPC],Penicillins [CS],beta Lactamase Inhibitors [MoA],beta Lactamase Inhibitor [EPC]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2021-07-28</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20211231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20200724</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>10544-277-20</NDCCode>
<PackageDescription>20 TABLET in 1 BOTTLE (10544-277-20)</PackageDescription>
<NDC11Code>10544-0277-20</NDC11Code>
<ProductNDC>10544-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Naproxen</ProprietaryName>
<NonProprietaryName>Naproxen</NonProprietaryName>
<DosageFormName>TABLET</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20091214</StartMarketingDate>
<MarketingCategoryName>ANDA</MarketingCategoryName>
<ApplicationNumber>ANDA078250</ApplicationNumber>
<LabelerName>Blenheim Pharmacal, Inc.</LabelerName>
<SubstanceName>NAPROXEN</SubstanceName>
<StrengthNumber>375</StrengthNumber>
<StrengthUnit>mg/1</StrengthUnit>
<Pharm_Classes>Cyclooxygenase Inhibitors [MoA],Nonsteroidal Anti-inflammatory Compounds [Chemical/Ingredient],Nonsteroidal Anti-inflammatory Drug [EPC]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2019-09-21</LastUpdate>
<ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
<IndicationAndUsage>Carefully consider the potential benefits and risks of naproxen, naproxen sodium and other treatment options before deciding to use naproxen and naproxen sodium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS). Naproxen as naproxen or naproxen sodium tablets are indicated: : 1 For the relief of the signs and symptoms of rheumatoid arthritis , 2 For the relief of the signs and symptoms of osteoarthritis , 3 For the relief of the signs and symptoms of ankylosing spondylitis , 4 For the relief of the signs and symptoms of juvenile arthritis.</IndicationAndUsage>
<Description>Naproxen USP is a proprionic acid derivative related to the arylacetic acid group of nonsteroidal anti-inflammatory drugs. The chemical names for naproxen USP and naproxen sodium USP are (S)-6-methoxy-α-methyl-2-naphthaleneacetic acid and (S)-6-methoxy-α-methyl-2-naphthaleneacetic acid, sodium salt, respectively. Naproxen USP and naproxen sodium USP have the following structures, respectively:. Naproxen USP has a molecular weight of 230.26 and a molecular formula of C14H14O3. Naproxen sodium USP has a molecular weight of 252.23 and a molecular formula of C14H13NaO3. Naproxen USP is an odorless, white to off-white crystalline substance. It is lipid-soluble, practically insoluble in water at low pH and freely soluble in water at high pH. The octanol/water partition coefficient of naproxen USP at pH 7.4 is 1.6 to 1.8. Naproxen sodium USP is a white to creamy white, crystalline solid, freely soluble in water at neutral pH. Naproxen tablets USP are available as light orange colored tablets containing 250 mg of naproxen USP, light orange colored tablets containing 375 mg of naproxen USP and light orange colored tablets containing 500 mg of naproxen USP for oral administration. The inactive ingredients are microcrystalline cellulose, croscarmellose sodium, iron oxides, povidone and magnesium stearate. Naproxen sodium tablets USP are available as blue tablets containing 275 mg of naproxen sodium USP and as blue tablets containing 550 mg of naproxen sodium USP for oral administration. The inactive ingredients are croscarmellose sodium, colloidal silicon dioxide, povidone, magnesium stearate, microcrystalline cellulose and talc. The coating suspension for the naproxen sodium 275 mg tablet may contain Opadry blue 03F50544. The coating suspension for the naproxen sodium 550 mg tablet may contain Opadry blue 03F50544.</Description>
</NDC>
<NDC>
<NDCCode>43744-277-20</NDCCode>
<PackageDescription>15 g in 1 DRUM (43744-277-20)</PackageDescription>
<NDC11Code>43744-0277-20</NDC11Code>
<ProductNDC>43744-277</ProductNDC>
<ProductTypeName>BULK INGREDIENT</ProductTypeName>
<NonProprietaryName>Diclofenac Sodium</NonProprietaryName>
<DosageFormName>POWDER</DosageFormName>
<StartMarketingDate>20120808</StartMarketingDate>
<EndMarketingDate>20130624</EndMarketingDate>
<MarketingCategoryName>BULK INGREDIENT</MarketingCategoryName>
<LabelerName>CBSCHEM LIMITED</LabelerName>
<SubstanceName>DICLOFENAC SODIUM</SubstanceName>
<StrengthNumber>1</StrengthNumber>
<StrengthUnit>g/g</StrengthUnit>
<Status>Deprecated</Status>
<LastUpdate>2014-02-04</LastUpdate>
<ListingRecordCertifiedThrough>20130624</ListingRecordCertifiedThrough>
</NDC>
<NDC>
<NDCCode>43744-277-22</NDCCode>
<PackageDescription>20 g in 1 DRUM (43744-277-22)</PackageDescription>
<NDC11Code>43744-0277-22</NDC11Code>
<ProductNDC>43744-277</ProductNDC>
<ProductTypeName>BULK INGREDIENT</ProductTypeName>
<NonProprietaryName>Diclofenac Sodium</NonProprietaryName>
<DosageFormName>POWDER</DosageFormName>
<StartMarketingDate>20120808</StartMarketingDate>
<EndMarketingDate>20130624</EndMarketingDate>
<MarketingCategoryName>BULK INGREDIENT</MarketingCategoryName>
<LabelerName>CBSCHEM LIMITED</LabelerName>
<SubstanceName>DICLOFENAC SODIUM</SubstanceName>
<StrengthNumber>1</StrengthNumber>
<StrengthUnit>g/g</StrengthUnit>
<Status>Deprecated</Status>
<LastUpdate>2014-02-04</LastUpdate>
<ListingRecordCertifiedThrough>20130624</ListingRecordCertifiedThrough>
</NDC>
<NDC>
<NDCCode>49999-277-20</NDCCode>
<PackageDescription>20 TABLET in 1 BOTTLE, PLASTIC (49999-277-20)</PackageDescription>
<NDC11Code>49999-0277-20</NDC11Code>
<ProductNDC>49999-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Hydrocodone Bitartrate And Acetaminophen</ProprietaryName>
<NonProprietaryName>Hydrocodone Bitartrate And Acetaminophen</NonProprietaryName>
<DosageFormName>TABLET</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20110205</StartMarketingDate>
<MarketingCategoryName>ANDA</MarketingCategoryName>
<ApplicationNumber>ANDA040084</ApplicationNumber>
<LabelerName>Lake Erie Medical DBA Quality Care Products LLC</LabelerName>
<SubstanceName>HYDROCODONE BITARTRATE; ACETAMINOPHEN</SubstanceName>
<StrengthNumber>10; 650</StrengthNumber>
<StrengthUnit>mg/1; mg/1</StrengthUnit>
<Pharm_Classes>Opioid Agonist [EPC],Opioid Agonists [MoA]</Pharm_Classes>
<DEASchedule>CIII</DEASchedule>
<Status>Deprecated</Status>
<LastUpdate>2016-03-11</LastUpdate>
</NDC>
<NDC>
<NDCCode>51079-277-20</NDCCode>
<PackageDescription>100 BLISTER PACK in 1 BOX, UNIT-DOSE (51079-277-20) > 1 TABLET in 1 BLISTER PACK (51079-277-01)</PackageDescription>
<NDC11Code>51079-0277-20</NDC11Code>
<ProductNDC>51079-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Propranolol Hydrochloride</ProprietaryName>
<NonProprietaryName>Propranolol Hydrochloride</NonProprietaryName>
<DosageFormName>TABLET</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20110920</StartMarketingDate>
<MarketingCategoryName>ANDA</MarketingCategoryName>
<ApplicationNumber>ANDA070213</ApplicationNumber>
<LabelerName>UDL Laboratories, Inc.</LabelerName>
<SubstanceName>PROPRANOLOL HYDROCHLORIDE</SubstanceName>
<StrengthNumber>10</StrengthNumber>
<StrengthUnit>mg/1</StrengthUnit>
<Pharm_Classes>Adrenergic beta-Antagonists [MoA],beta-Adrenergic Blocker [EPC]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2015-04-10</LastUpdate>
</NDC>
<NDC>
<NDCCode>52584-277-01</NDCCode>
<PackageDescription>1 VIAL, MULTI-DOSE in 1 BAG (52584-277-01) > 20 mL in 1 VIAL, MULTI-DOSE</PackageDescription>
<NDC11Code>52584-0277-01</NDC11Code>
<ProductNDC>52584-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Lidocaine Hydrochloride</ProprietaryName>
<NonProprietaryName>Lidocaine Hydrochloride Anhydrous</NonProprietaryName>
<DosageFormName>INJECTION, SOLUTION</DosageFormName>
<RouteName>INFILTRATION; PERINEURAL</RouteName>
<StartMarketingDate>20100901</StartMarketingDate>
<EndMarketingDate>20240301</EndMarketingDate>
<MarketingCategoryName>ANDA</MarketingCategoryName>
<ApplicationNumber>ANDA088327</ApplicationNumber>
<LabelerName>General Injectables & Vaccines, Inc</LabelerName>
<SubstanceName>LIDOCAINE HYDROCHLORIDE</SubstanceName>
<StrengthNumber>20</StrengthNumber>
<StrengthUnit>mg/mL</StrengthUnit>
<Pharm_Classes>Amide Local Anesthetic [EPC], Amides [CS], Antiarrhythmic [EPC], Local Anesthesia [PE]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2023-01-03</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20100901</StartMarketingDatePackage>
<EndMarketingDatePackage>20230101</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>Lidocaine Hydrochloride Injection, USP is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.</IndicationAndUsage>
<Description>Lidocaine Hydrochloride Injection, USP is a sterile, nonpyrogenic solution of lidocaine hydrochloride in water for injection for parenteral administration in various concentrations with characteristics as follows. Multiple-dose vials contain 0.1% of methylparaben added as preservative. May contain sodium hydroxide and/or hydrochloric acid for pH adjustment. The pH is 6.5 (5.0 to 7.0). See HOW SUPPLIED section for various sizes and strengths. Lidocaine is a local anesthetic of the amide type. Lidocaine Hydrochloride, USP is chemically designated 2-(diethylamino)-N-(2,6-dimethylphenyl)-acetamide monohydrochloride monohydrate, a white powder freely soluble in water. The molecular weight is 288.82. It has the following structural formula. The semi-rigid vial used for the plastic vials is fabricated from a specially formulated polyolefin. It is a copolymer of ethylene and propylene. The safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers. The container requires no vapor barrier to maintain the proper drug concentration.</Description>
</NDC>
<NDC>
<NDCCode>57687-277-20</NDCCode>
<PackageDescription>1 BOTTLE, DROPPER in 1 CARTON (57687-277-20) > 20 mL in 1 BOTTLE, DROPPER</PackageDescription>
<NDC11Code>57687-0277-20</NDC11Code>
<ProductNDC>57687-277</ProductNDC>
<ProductTypeName>HUMAN OTC DRUG</ProductTypeName>
<ProprietaryName>Bach Original Flower Remedies</ProprietaryName>
<NonProprietaryName>Scleranthus Annuus Whole</NonProprietaryName>
<DosageFormName>SOLUTION</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20020101</StartMarketingDate>
<MarketingCategoryName>UNAPPROVED HOMEOPATHIC</MarketingCategoryName>
<LabelerName>Nelson Bach USA Limited</LabelerName>
<SubstanceName>SCLERANTHUS ANNUUS WHOLE</SubstanceName>
<StrengthNumber>5</StrengthNumber>
<StrengthUnit>[hp_X]/.095mL</StrengthUnit>
<Status>Active</Status>
<LastUpdate>2020-06-24</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20261231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20020101</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>For relief of naturally occurring simple nervous tension.</IndicationAndUsage>
</NDC>
<NDC>
<NDCCode>67046-277-20</NDCCode>
<PackageDescription>20 TABLET in 1 BLISTER PACK (67046-277-20)</PackageDescription>
<NDC11Code>67046-0277-20</NDC11Code>
<ProductNDC>67046-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Hydrochlorothiazide</ProprietaryName>
<NonProprietaryName>Hydrochlorothiazide</NonProprietaryName>
<DosageFormName>TABLET</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20170928</StartMarketingDate>
<MarketingCategoryName>ANDA</MarketingCategoryName>
<ApplicationNumber>ANDA040807</ApplicationNumber>
<LabelerName>Contract Pharmacy Services-PA</LabelerName>
<SubstanceName>HYDROCHLOROTHIAZIDE</SubstanceName>
<StrengthNumber>25</StrengthNumber>
<StrengthUnit>mg/1</StrengthUnit>
<Pharm_Classes>Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [CS]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2022-01-04</LastUpdate>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20211231</ListingRecordCertifiedThrough>
<IndicationAndUsage>Hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.</IndicationAndUsage>
<Description>Hydrochlorothiazide is a diuretic and antihypertensive. It is the 3,4-dihydro derivative of chlorothiazide. It is chemically designated as 6-chloro-3,4-dihydro- 2H-1,2,4-benzothiadiazine- 7-sulfonamide 1,1-dioxide and has the following structural formula:. C 7H 8ClN 3O 4S 2 M.W. 297.74. Hydrochlorothiazide is a white, or practically white, crystalline powder which is slightly soluble in water, but freely soluble in sodium hydroxide solution. Each tablet for oral administration contains 12.5 mg, 25 mg and 50 mg hydrochlorothiazide, USP. In addition, each tablet contains the following inactive ingredients: corn starch, dibasic calcium phosphate, lactose monohydrate, magnesium stearate, pregelatinized starch, and sodium starch glycolate.Tablets of 12.5 mg and 25 mg strengths also contain FD&C yellow #6.</Description>
</NDC>
<NDC>
<NDCCode>69452-277-20</NDCCode>
<PackageDescription>100 TABLET in 1 BOTTLE (69452-277-20) </PackageDescription>
<NDC11Code>69452-0277-20</NDC11Code>
<ProductNDC>69452-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Dexamethasone</ProprietaryName>
<NonProprietaryName>Dexamethasone</NonProprietaryName>
<DosageFormName>TABLET</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20230801</StartMarketingDate>
<MarketingCategoryName>ANDA</MarketingCategoryName>
<ApplicationNumber>ANDA217001</ApplicationNumber>
<LabelerName>Bionpharma Inc.,</LabelerName>
<SubstanceName>DEXAMETHASONE</SubstanceName>
<StrengthNumber>4</StrengthNumber>
<StrengthUnit>mg/1</StrengthUnit>
<Pharm_Classes>Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2025-03-07</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20261231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20230801</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous: Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.</IndicationAndUsage>
<Description>Dexamethasone tablets, USP, for oral administration, are supplied as 4 mg, and 6 mg. Inactive ingredients are corn starch, D&C yellow 10 (4 mg), FD&C blue 1 (6 mg), lactose monohydrate, and magnesium stearate. The molecular weight for dexamethasone is 392.5 g/mol. It is designated chemically as 9-fluoro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione. The molecular formula is C 22H 29FO 5 and the structural formula is:. Dexamethasone, USP a synthetic adrenocortical steroid, is a white to almost-white, crystalline powder. It is stable in air. It is practically insoluble in water, very slightly soluble in ether, slightly soluble in methylene chloride and chloroform, and sparingly soluble in methanol, ethanol (96 %), acetone and 1,4 dioxane.</Description>
</NDC>
<NDC>
<NDCCode>72789-277-20</NDCCode>
<PackageDescription>20 CAPSULE in 1 BOTTLE, PLASTIC (72789-277-20) </PackageDescription>
<NDC11Code>72789-0277-20</NDC11Code>
<ProductNDC>72789-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Doxycycline Hyclate</ProprietaryName>
<NonProprietaryName>Doxycycline Hyclate</NonProprietaryName>
<DosageFormName>CAPSULE</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>19860710</StartMarketingDate>
<MarketingCategoryName>ANDA</MarketingCategoryName>
<ApplicationNumber>ANDA062676</ApplicationNumber>
<LabelerName>PD-Rx Pharmaceuticals, Inc.</LabelerName>
<SubstanceName>DOXYCYCLINE HYCLATE</SubstanceName>
<StrengthNumber>100</StrengthNumber>
<StrengthUnit>mg/1</StrengthUnit>
<Pharm_Classes>Tetracycline-class Drug [EPC], Tetracyclines [CS]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2026-07-21</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20271231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20221118</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</IndicationAndUsage>
<Description>Doxycycline hyclate is an antibacterial drug synthetically derived from oxytetracycline, and is available as doxycycline hyclate (doxycycline hydrochloride hemiethanolate hemihydrate) capsules and tablets for oral administration. The chemical designation of this light-yellow crystalline powder is alpha-6-deoxy-5-oxytetracycline. Doxycycline has a high degree of lipoid solubility and a low affinity for calcium binding. It is highly stable in normal human serum. Doxycycline will not degrade into an epianhydro form. Doxycycline hyclate has the following structural formula. Each capsule for oral administration contains doxycycline hyclate equivalent to 50 mg or 100 mg doxycycline (anhydrous). Inactive ingredients for capsules are: anhydrous lactose, croscarmellose sodium, FD&C Blue #1, gelatin, magnesium stearate, microcrystalline cellulose, and titanium dioxide. Each tablet for oral administration contains doxycycline hyclate equivalent to 100 mg doxycycline. Inactive ingredients for tablets are: lactose monohydrate, carnauba wax, croscarmellose sodium, D&C Yellow #10 aluminum lake, FD&C Red #40 aluminum lake, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, and titanium dioxide.</Description>
</NDC>
<NDC>
<NDCCode>73069-277-51</NDCCode>
<PackageDescription>1 VIAL, MULTI-DOSE in 1 BOX (73069-277-51) > 20 mL in 1 VIAL, MULTI-DOSE</PackageDescription>
<NDC11Code>73069-0277-51</NDC11Code>
<ProductNDC>73069-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Viatrexx-ki-ub</ProprietaryName>
<NonProprietaryName>Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone</NonProprietaryName>
<DosageFormName>INJECTION</DosageFormName>
<RouteName>INTRAMUSCULAR; INTRAVENOUS; PARENTERAL; SUBCUTANEOUS</RouteName>
<StartMarketingDate>20190329</StartMarketingDate>
<MarketingCategoryName>UNAPPROVED DRUG OTHER</MarketingCategoryName>
<LabelerName>VIATREXX BIO INCORPORATED</LabelerName>
<SubstanceName>NITRIC ACID; SUCCINIC ACID; ESCHERICHIA COLI; BERBERIS VULGARIS ROOT; EQUISETUM HYEMALE; POTASSIUM NITRATE; BEEF KIDNEY; PORK KIDNEY; METHYL BLUE; ONONIS SPINOSA WHOLE; CLERODENDRANTHUS SPICATUS LEAF; CHONDRODENDRON TOMENTOSUM ROOT; PLANTAGO MAJOR; SMILAX ORNATA ROOT; SOLIDAGO VIRGAUREA FLOWERING TOP; BOS TAURUS URETER; SUS SCROFA URETER; BOS TAURUS URINARY BLADDER; SUS SCROFA URINARY BLADDER; PROTEUS INCONSTANS; HIERACIUM PILOSELLA WHOLE; QUINHYDRONE</SubstanceName>
<StrengthNumber>31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31</StrengthNumber>
<StrengthUnit>[kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL</StrengthUnit>
<Pharm_Classes>Melanin Synthesis Inhibitor [EPC],Melanin Synthesis Inhibitors [MoA],Depigmenting Activity [PE]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2021-01-01</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20201231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20190506</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>73069-277-52</NDCCode>
<PackageDescription>3 VIAL, MULTI-DOSE in 1 BOX (73069-277-52) > 20 mL in 1 VIAL, MULTI-DOSE</PackageDescription>
<NDC11Code>73069-0277-52</NDC11Code>
<ProductNDC>73069-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Viatrexx-ki-ub</ProprietaryName>
<NonProprietaryName>Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone</NonProprietaryName>
<DosageFormName>INJECTION</DosageFormName>
<RouteName>INTRAMUSCULAR; INTRAVENOUS; PARENTERAL; SUBCUTANEOUS</RouteName>
<StartMarketingDate>20190329</StartMarketingDate>
<MarketingCategoryName>UNAPPROVED DRUG OTHER</MarketingCategoryName>
<LabelerName>VIATREXX BIO INCORPORATED</LabelerName>
<SubstanceName>NITRIC ACID; SUCCINIC ACID; ESCHERICHIA COLI; BERBERIS VULGARIS ROOT; EQUISETUM HYEMALE; POTASSIUM NITRATE; BEEF KIDNEY; PORK KIDNEY; METHYL BLUE; ONONIS SPINOSA WHOLE; CLERODENDRANTHUS SPICATUS LEAF; CHONDRODENDRON TOMENTOSUM ROOT; PLANTAGO MAJOR; SMILAX ORNATA ROOT; SOLIDAGO VIRGAUREA FLOWERING TOP; BOS TAURUS URETER; SUS SCROFA URETER; BOS TAURUS URINARY BLADDER; SUS SCROFA URINARY BLADDER; PROTEUS INCONSTANS; HIERACIUM PILOSELLA WHOLE; QUINHYDRONE</SubstanceName>
<StrengthNumber>31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31</StrengthNumber>
<StrengthUnit>[kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL</StrengthUnit>
<Pharm_Classes>Melanin Synthesis Inhibitor [EPC],Melanin Synthesis Inhibitors [MoA],Depigmenting Activity [PE]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2021-01-01</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20201231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20190506</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>73069-277-53</NDCCode>
<PackageDescription>5 VIAL, MULTI-DOSE in 1 BOX (73069-277-53) > 20 mL in 1 VIAL, MULTI-DOSE</PackageDescription>
<NDC11Code>73069-0277-53</NDC11Code>
<ProductNDC>73069-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Viatrexx-ki-ub</ProprietaryName>
<NonProprietaryName>Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone</NonProprietaryName>
<DosageFormName>INJECTION</DosageFormName>
<RouteName>INTRAMUSCULAR; INTRAVENOUS; PARENTERAL; SUBCUTANEOUS</RouteName>
<StartMarketingDate>20190329</StartMarketingDate>
<MarketingCategoryName>UNAPPROVED DRUG OTHER</MarketingCategoryName>
<LabelerName>VIATREXX BIO INCORPORATED</LabelerName>
<SubstanceName>NITRIC ACID; SUCCINIC ACID; ESCHERICHIA COLI; BERBERIS VULGARIS ROOT; EQUISETUM HYEMALE; POTASSIUM NITRATE; BEEF KIDNEY; PORK KIDNEY; METHYL BLUE; ONONIS SPINOSA WHOLE; CLERODENDRANTHUS SPICATUS LEAF; CHONDRODENDRON TOMENTOSUM ROOT; PLANTAGO MAJOR; SMILAX ORNATA ROOT; SOLIDAGO VIRGAUREA FLOWERING TOP; BOS TAURUS URETER; SUS SCROFA URETER; BOS TAURUS URINARY BLADDER; SUS SCROFA URINARY BLADDER; PROTEUS INCONSTANS; HIERACIUM PILOSELLA WHOLE; QUINHYDRONE</SubstanceName>
<StrengthNumber>31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31</StrengthNumber>
<StrengthUnit>[kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL</StrengthUnit>
<Pharm_Classes>Melanin Synthesis Inhibitor [EPC],Melanin Synthesis Inhibitors [MoA],Depigmenting Activity [PE]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2021-01-01</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20201231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20190506</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>73069-277-54</NDCCode>
<PackageDescription>6 VIAL, MULTI-DOSE in 1 BOX (73069-277-54) > 20 mL in 1 VIAL, MULTI-DOSE</PackageDescription>
<NDC11Code>73069-0277-54</NDC11Code>
<ProductNDC>73069-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Viatrexx-ki-ub</ProprietaryName>
<NonProprietaryName>Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone</NonProprietaryName>
<DosageFormName>INJECTION</DosageFormName>
<RouteName>INTRAMUSCULAR; INTRAVENOUS; PARENTERAL; SUBCUTANEOUS</RouteName>
<StartMarketingDate>20190329</StartMarketingDate>
<MarketingCategoryName>UNAPPROVED DRUG OTHER</MarketingCategoryName>
<LabelerName>VIATREXX BIO INCORPORATED</LabelerName>
<SubstanceName>NITRIC ACID; SUCCINIC ACID; ESCHERICHIA COLI; BERBERIS VULGARIS ROOT; EQUISETUM HYEMALE; POTASSIUM NITRATE; BEEF KIDNEY; PORK KIDNEY; METHYL BLUE; ONONIS SPINOSA WHOLE; CLERODENDRANTHUS SPICATUS LEAF; CHONDRODENDRON TOMENTOSUM ROOT; PLANTAGO MAJOR; SMILAX ORNATA ROOT; SOLIDAGO VIRGAUREA FLOWERING TOP; BOS TAURUS URETER; SUS SCROFA URETER; BOS TAURUS URINARY BLADDER; SUS SCROFA URINARY BLADDER; PROTEUS INCONSTANS; HIERACIUM PILOSELLA WHOLE; QUINHYDRONE</SubstanceName>
<StrengthNumber>31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31</StrengthNumber>
<StrengthUnit>[kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL</StrengthUnit>
<Pharm_Classes>Melanin Synthesis Inhibitor [EPC],Melanin Synthesis Inhibitors [MoA],Depigmenting Activity [PE]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2021-01-01</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20201231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20190506</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>73069-277-55</NDCCode>
<PackageDescription>10 VIAL, MULTI-DOSE in 1 BOX (73069-277-55) > 20 mL in 1 VIAL, MULTI-DOSE</PackageDescription>
<NDC11Code>73069-0277-55</NDC11Code>
<ProductNDC>73069-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Viatrexx-ki-ub</ProprietaryName>
<NonProprietaryName>Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone</NonProprietaryName>
<DosageFormName>INJECTION</DosageFormName>
<RouteName>INTRAMUSCULAR; INTRAVENOUS; PARENTERAL; SUBCUTANEOUS</RouteName>
<StartMarketingDate>20190329</StartMarketingDate>
<MarketingCategoryName>UNAPPROVED DRUG OTHER</MarketingCategoryName>
<LabelerName>VIATREXX BIO INCORPORATED</LabelerName>
<SubstanceName>NITRIC ACID; SUCCINIC ACID; ESCHERICHIA COLI; BERBERIS VULGARIS ROOT; EQUISETUM HYEMALE; POTASSIUM NITRATE; BEEF KIDNEY; PORK KIDNEY; METHYL BLUE; ONONIS SPINOSA WHOLE; CLERODENDRANTHUS SPICATUS LEAF; CHONDRODENDRON TOMENTOSUM ROOT; PLANTAGO MAJOR; SMILAX ORNATA ROOT; SOLIDAGO VIRGAUREA FLOWERING TOP; BOS TAURUS URETER; SUS SCROFA URETER; BOS TAURUS URINARY BLADDER; SUS SCROFA URINARY BLADDER; PROTEUS INCONSTANS; HIERACIUM PILOSELLA WHOLE; QUINHYDRONE</SubstanceName>
<StrengthNumber>31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31</StrengthNumber>
<StrengthUnit>[kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL</StrengthUnit>
<Pharm_Classes>Melanin Synthesis Inhibitor [EPC],Melanin Synthesis Inhibitors [MoA],Depigmenting Activity [PE]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2021-01-01</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20201231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20190506</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>73069-277-56</NDCCode>
<PackageDescription>12 VIAL, MULTI-DOSE in 1 BOX (73069-277-56) > 20 mL in 1 VIAL, MULTI-DOSE</PackageDescription>
<NDC11Code>73069-0277-56</NDC11Code>
<ProductNDC>73069-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Viatrexx-ki-ub</ProprietaryName>
<NonProprietaryName>Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone</NonProprietaryName>
<DosageFormName>INJECTION</DosageFormName>
<RouteName>INTRAMUSCULAR; INTRAVENOUS; PARENTERAL; SUBCUTANEOUS</RouteName>
<StartMarketingDate>20190329</StartMarketingDate>
<MarketingCategoryName>UNAPPROVED DRUG OTHER</MarketingCategoryName>
<LabelerName>VIATREXX BIO INCORPORATED</LabelerName>
<SubstanceName>NITRIC ACID; SUCCINIC ACID; ESCHERICHIA COLI; BERBERIS VULGARIS ROOT; EQUISETUM HYEMALE; POTASSIUM NITRATE; BEEF KIDNEY; PORK KIDNEY; METHYL BLUE; ONONIS SPINOSA WHOLE; CLERODENDRANTHUS SPICATUS LEAF; CHONDRODENDRON TOMENTOSUM ROOT; PLANTAGO MAJOR; SMILAX ORNATA ROOT; SOLIDAGO VIRGAUREA FLOWERING TOP; BOS TAURUS URETER; SUS SCROFA URETER; BOS TAURUS URINARY BLADDER; SUS SCROFA URINARY BLADDER; PROTEUS INCONSTANS; HIERACIUM PILOSELLA WHOLE; QUINHYDRONE</SubstanceName>
<StrengthNumber>31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31</StrengthNumber>
<StrengthUnit>[kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL</StrengthUnit>
<Pharm_Classes>Melanin Synthesis Inhibitor [EPC],Melanin Synthesis Inhibitors [MoA],Depigmenting Activity [PE]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2021-01-01</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20201231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20190506</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>73069-277-57</NDCCode>
<PackageDescription>25 VIAL, MULTI-DOSE in 1 BOX (73069-277-57) > 20 mL in 1 VIAL, MULTI-DOSE</PackageDescription>
<NDC11Code>73069-0277-57</NDC11Code>
<ProductNDC>73069-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Viatrexx-ki-ub</ProprietaryName>
<NonProprietaryName>Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone</NonProprietaryName>
<DosageFormName>INJECTION</DosageFormName>
<RouteName>INTRAMUSCULAR; INTRAVENOUS; PARENTERAL; SUBCUTANEOUS</RouteName>
<StartMarketingDate>20190329</StartMarketingDate>
<MarketingCategoryName>UNAPPROVED DRUG OTHER</MarketingCategoryName>
<LabelerName>VIATREXX BIO INCORPORATED</LabelerName>
<SubstanceName>NITRIC ACID; SUCCINIC ACID; ESCHERICHIA COLI; BERBERIS VULGARIS ROOT; EQUISETUM HYEMALE; POTASSIUM NITRATE; BEEF KIDNEY; PORK KIDNEY; METHYL BLUE; ONONIS SPINOSA WHOLE; CLERODENDRANTHUS SPICATUS LEAF; CHONDRODENDRON TOMENTOSUM ROOT; PLANTAGO MAJOR; SMILAX ORNATA ROOT; SOLIDAGO VIRGAUREA FLOWERING TOP; BOS TAURUS URETER; SUS SCROFA URETER; BOS TAURUS URINARY BLADDER; SUS SCROFA URINARY BLADDER; PROTEUS INCONSTANS; HIERACIUM PILOSELLA WHOLE; QUINHYDRONE</SubstanceName>
<StrengthNumber>31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31</StrengthNumber>
<StrengthUnit>[kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL</StrengthUnit>
<Pharm_Classes>Melanin Synthesis Inhibitor [EPC],Melanin Synthesis Inhibitors [MoA],Depigmenting Activity [PE]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2021-01-01</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20201231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20190506</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>73069-277-58</NDCCode>
<PackageDescription>50 VIAL, MULTI-DOSE in 1 BOX (73069-277-58) > 20 mL in 1 VIAL, MULTI-DOSE</PackageDescription>
<NDC11Code>73069-0277-58</NDC11Code>
<ProductNDC>73069-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Viatrexx-ki-ub</ProprietaryName>
<NonProprietaryName>Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone</NonProprietaryName>
<DosageFormName>INJECTION</DosageFormName>
<RouteName>INTRAMUSCULAR; INTRAVENOUS; PARENTERAL; SUBCUTANEOUS</RouteName>
<StartMarketingDate>20190329</StartMarketingDate>
<MarketingCategoryName>UNAPPROVED DRUG OTHER</MarketingCategoryName>
<LabelerName>VIATREXX BIO INCORPORATED</LabelerName>
<SubstanceName>NITRIC ACID; SUCCINIC ACID; ESCHERICHIA COLI; BERBERIS VULGARIS ROOT; EQUISETUM HYEMALE; POTASSIUM NITRATE; BEEF KIDNEY; PORK KIDNEY; METHYL BLUE; ONONIS SPINOSA WHOLE; CLERODENDRANTHUS SPICATUS LEAF; CHONDRODENDRON TOMENTOSUM ROOT; PLANTAGO MAJOR; SMILAX ORNATA ROOT; SOLIDAGO VIRGAUREA FLOWERING TOP; BOS TAURUS URETER; SUS SCROFA URETER; BOS TAURUS URINARY BLADDER; SUS SCROFA URINARY BLADDER; PROTEUS INCONSTANS; HIERACIUM PILOSELLA WHOLE; QUINHYDRONE</SubstanceName>
<StrengthNumber>31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31</StrengthNumber>
<StrengthUnit>[kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL</StrengthUnit>
<Pharm_Classes>Melanin Synthesis Inhibitor [EPC],Melanin Synthesis Inhibitors [MoA],Depigmenting Activity [PE]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2021-01-01</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20201231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20190506</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>73069-277-59</NDCCode>
<PackageDescription>100 VIAL, MULTI-DOSE in 1 BOX (73069-277-59) > 20 mL in 1 VIAL, MULTI-DOSE</PackageDescription>
<NDC11Code>73069-0277-59</NDC11Code>
<ProductNDC>73069-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Viatrexx-ki-ub</ProprietaryName>
<NonProprietaryName>Nitric Acid , Succinic Acid , Escherichia Coli , Berberis Vulgaris Root , Equisetum Hyemale , Potassium Nitrate , Beef Kidney , Pork Kidney , Methyl Blue , Ononis Spinosa Whole , Clerodendranthus Spicatus Leaf , Chondrodendron Tomentosum Root , Plantago Major , Smilax Regelii Root , Solidago Virgaurea Flowering Top , Bos Taurus Ureter , Sus Scrofa Ureter , Bos Taurus Urinary Bladder , Sus Scrofa Urinary Bladder , Proteus Inconstans , Hieracium Pilosella Whole And Quinhydrone</NonProprietaryName>
<DosageFormName>INJECTION</DosageFormName>
<RouteName>INTRAMUSCULAR; INTRAVENOUS; PARENTERAL; SUBCUTANEOUS</RouteName>
<StartMarketingDate>20190329</StartMarketingDate>
<MarketingCategoryName>UNAPPROVED DRUG OTHER</MarketingCategoryName>
<LabelerName>VIATREXX BIO INCORPORATED</LabelerName>
<SubstanceName>NITRIC ACID; SUCCINIC ACID; ESCHERICHIA COLI; BERBERIS VULGARIS ROOT; EQUISETUM HYEMALE; POTASSIUM NITRATE; BEEF KIDNEY; PORK KIDNEY; METHYL BLUE; ONONIS SPINOSA WHOLE; CLERODENDRANTHUS SPICATUS LEAF; CHONDRODENDRON TOMENTOSUM ROOT; PLANTAGO MAJOR; SMILAX ORNATA ROOT; SOLIDAGO VIRGAUREA FLOWERING TOP; BOS TAURUS URETER; SUS SCROFA URETER; BOS TAURUS URINARY BLADDER; SUS SCROFA URINARY BLADDER; PROTEUS INCONSTANS; HIERACIUM PILOSELLA WHOLE; QUINHYDRONE</SubstanceName>
<StrengthNumber>31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31; 31</StrengthNumber>
<StrengthUnit>[kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL; [kp_C]/mL</StrengthUnit>
<Pharm_Classes>Melanin Synthesis Inhibitor [EPC],Melanin Synthesis Inhibitors [MoA],Depigmenting Activity [PE]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2021-01-01</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20201231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20190506</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
</NDC>
<NDC>
<NDCCode>10702-277-03</NDCCode>
<PackageDescription>30 TABLET in 1 BOTTLE (10702-277-03) </PackageDescription>
<NDC11Code>10702-0277-03</NDC11Code>
<ProductNDC>10702-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Leflunomide</ProprietaryName>
<NonProprietaryName>Leflunomide</NonProprietaryName>
<DosageFormName>TABLET</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20200723</StartMarketingDate>
<MarketingCategoryName>ANDA</MarketingCategoryName>
<ApplicationNumber>ANDA212453</ApplicationNumber>
<LabelerName>KVK-Tech, Inc.</LabelerName>
<SubstanceName>LEFLUNOMIDE</SubstanceName>
<StrengthNumber>10</StrengthNumber>
<StrengthUnit>mg/1</StrengthUnit>
<Pharm_Classes>Antirheumatic Agent [EPC]</Pharm_Classes>
<Status>Active</Status>
<LastUpdate>2025-06-25</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20261231</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>20200723</StartMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>Leflunomide tablets are indicated for the treatment of adults with active rheumatoid arthritis (RA).</IndicationAndUsage>
<Description>Leflunomide is a pyrimidine synthesis inhibitor. The chemical name for leflunomide is 4-Isoxazolecarboxamide, 5-methyl-N-[4-(trifluoromethyl)-phenyl]-. It has an empirical formula C12H9F3N2O2, a molecular weight of 270.21 and the following structural formula. Leflunomide tablets are available for oral administration as film coated tablets containing 10, or 20 mg of active drug. Combined with leflunomide are the following inactive ingredients: colloidal silicon dioxide, crospovidone, hypromellose, lactose monohydrate, magnesium stearate, polyethylene glycol, povidone, corn starch, talc, titanium dioxide, and yellow ferric oxide (20 mg tablet only).</Description>
</NDC>
<NDC>
<NDCCode>21695-277-15</NDCCode>
<PackageDescription>15 CAPSULE in 1 BOTTLE (21695-277-15)</PackageDescription>
<NDC11Code>21695-0277-15</NDC11Code>
<ProductNDC>21695-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Lyrica</ProprietaryName>
<NonProprietaryName>Pregabalin</NonProprietaryName>
<DosageFormName>CAPSULE</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20050610</StartMarketingDate>
<MarketingCategoryName>NDA</MarketingCategoryName>
<ApplicationNumber>NDA021724</ApplicationNumber>
<LabelerName>Rebel Distributors Corp</LabelerName>
<SubstanceName>PREGABALIN</SubstanceName>
<StrengthNumber>50</StrengthNumber>
<StrengthUnit>mg/1</StrengthUnit>
<DEASchedule>CV</DEASchedule>
<Status>Deprecated</Status>
<LastUpdate>2019-09-21</LastUpdate>
<ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
<IndicationAndUsage>LYRICA is indicated for.</IndicationAndUsage>
<Description>Pregabalin is described chemically as (S)-3-(aminomethyl)-5-methylhexanoic acid. The molecular formula is C8H17NO2 and the molecular weight is 159.23. The chemical structure of pregabalin is. Pregabalin is a white to off-white, crystalline solid with a pKa1 of 4.2 and a pKa2 of 10.6. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05M phosphate buffer) at pH 7.4 is – 1.35. LYRICA (pregabalin) Capsules are administered orally and are supplied as imprinted hard-shell capsules containing 25, 50, 75, 100, 150, 200, 225, and 300 mg of pregabalin, along with lactose monohydrate, cornstarch, and talc as inactive ingredients. The capsule shells contain gelatin and titanium dioxide. In addition, the orange capsule shells contain red iron oxide and the white capsule shells contain sodium lauryl sulfate and colloidal silicon dioxide. Colloidal silicon dioxide is a manufacturing aid that may or may not be present in the capsule shells. The imprinting ink contains shellac, black iron oxide, propylene glycol, and potassium hydroxide. LYRICA (pregabalin) oral solution, 20 mg/mL, is administered orally and is supplied as a clear, colorless solution contained in a 16 fluid ounce white HDPE bottle with a polyethylene-lined closure. The oral solution contains 20 mg/mL of pregabalin, along with methylparaben, propylparaben, monobasic sodium phosphate anhydrous, dibasic sodium phosphate anhydrous, sucralose, artificial strawberry #11545 and purified water as inactive ingredients.</Description>
</NDC>
<NDC>
<NDCCode>21695-277-30</NDCCode>
<PackageDescription>30 CAPSULE in 1 BOTTLE (21695-277-30)</PackageDescription>
<NDC11Code>21695-0277-30</NDC11Code>
<ProductNDC>21695-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Lyrica</ProprietaryName>
<NonProprietaryName>Pregabalin</NonProprietaryName>
<DosageFormName>CAPSULE</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20050610</StartMarketingDate>
<MarketingCategoryName>NDA</MarketingCategoryName>
<ApplicationNumber>NDA021724</ApplicationNumber>
<LabelerName>Rebel Distributors Corp</LabelerName>
<SubstanceName>PREGABALIN</SubstanceName>
<StrengthNumber>50</StrengthNumber>
<StrengthUnit>mg/1</StrengthUnit>
<DEASchedule>CV</DEASchedule>
<Status>Deprecated</Status>
<LastUpdate>2019-09-21</LastUpdate>
<ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
<IndicationAndUsage>LYRICA is indicated for.</IndicationAndUsage>
<Description>Pregabalin is described chemically as (S)-3-(aminomethyl)-5-methylhexanoic acid. The molecular formula is C8H17NO2 and the molecular weight is 159.23. The chemical structure of pregabalin is. Pregabalin is a white to off-white, crystalline solid with a pKa1 of 4.2 and a pKa2 of 10.6. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05M phosphate buffer) at pH 7.4 is – 1.35. LYRICA (pregabalin) Capsules are administered orally and are supplied as imprinted hard-shell capsules containing 25, 50, 75, 100, 150, 200, 225, and 300 mg of pregabalin, along with lactose monohydrate, cornstarch, and talc as inactive ingredients. The capsule shells contain gelatin and titanium dioxide. In addition, the orange capsule shells contain red iron oxide and the white capsule shells contain sodium lauryl sulfate and colloidal silicon dioxide. Colloidal silicon dioxide is a manufacturing aid that may or may not be present in the capsule shells. The imprinting ink contains shellac, black iron oxide, propylene glycol, and potassium hydroxide. LYRICA (pregabalin) oral solution, 20 mg/mL, is administered orally and is supplied as a clear, colorless solution contained in a 16 fluid ounce white HDPE bottle with a polyethylene-lined closure. The oral solution contains 20 mg/mL of pregabalin, along with methylparaben, propylparaben, monobasic sodium phosphate anhydrous, dibasic sodium phosphate anhydrous, sucralose, artificial strawberry #11545 and purified water as inactive ingredients.</Description>
</NDC>
<NDC>
<NDCCode>21695-277-90</NDCCode>
<PackageDescription>90 CAPSULE in 1 BOTTLE (21695-277-90)</PackageDescription>
<NDC11Code>21695-0277-90</NDC11Code>
<ProductNDC>21695-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Lyrica</ProprietaryName>
<NonProprietaryName>Pregabalin</NonProprietaryName>
<DosageFormName>CAPSULE</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20050610</StartMarketingDate>
<MarketingCategoryName>NDA</MarketingCategoryName>
<ApplicationNumber>NDA021724</ApplicationNumber>
<LabelerName>Rebel Distributors Corp</LabelerName>
<SubstanceName>PREGABALIN</SubstanceName>
<StrengthNumber>50</StrengthNumber>
<StrengthUnit>mg/1</StrengthUnit>
<DEASchedule>CV</DEASchedule>
<Status>Deprecated</Status>
<LastUpdate>2019-09-21</LastUpdate>
<ProductNdcExcludeFlag>E</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>20171231</ListingRecordCertifiedThrough>
<IndicationAndUsage>LYRICA is indicated for.</IndicationAndUsage>
<Description>Pregabalin is described chemically as (S)-3-(aminomethyl)-5-methylhexanoic acid. The molecular formula is C8H17NO2 and the molecular weight is 159.23. The chemical structure of pregabalin is. Pregabalin is a white to off-white, crystalline solid with a pKa1 of 4.2 and a pKa2 of 10.6. It is freely soluble in water and both basic and acidic aqueous solutions. The log of the partition coefficient (n-octanol/0.05M phosphate buffer) at pH 7.4 is – 1.35. LYRICA (pregabalin) Capsules are administered orally and are supplied as imprinted hard-shell capsules containing 25, 50, 75, 100, 150, 200, 225, and 300 mg of pregabalin, along with lactose monohydrate, cornstarch, and talc as inactive ingredients. The capsule shells contain gelatin and titanium dioxide. In addition, the orange capsule shells contain red iron oxide and the white capsule shells contain sodium lauryl sulfate and colloidal silicon dioxide. Colloidal silicon dioxide is a manufacturing aid that may or may not be present in the capsule shells. The imprinting ink contains shellac, black iron oxide, propylene glycol, and potassium hydroxide. LYRICA (pregabalin) oral solution, 20 mg/mL, is administered orally and is supplied as a clear, colorless solution contained in a 16 fluid ounce white HDPE bottle with a polyethylene-lined closure. The oral solution contains 20 mg/mL of pregabalin, along with methylparaben, propylparaben, monobasic sodium phosphate anhydrous, dibasic sodium phosphate anhydrous, sucralose, artificial strawberry #11545 and purified water as inactive ingredients.</Description>
</NDC>
<NDC>
<NDCCode>27808-277-01</NDCCode>
<PackageDescription>30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (27808-277-01) </PackageDescription>
<NDC11Code>27808-0277-01</NDC11Code>
<ProductNDC>27808-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Olmesartan Medoxomil</ProprietaryName>
<NonProprietaryName>Olmesartan Medoxomil</NonProprietaryName>
<DosageFormName>TABLET, FILM COATED</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20230520</StartMarketingDate>
<EndMarketingDate>20250131</EndMarketingDate>
<MarketingCategoryName>ANDA</MarketingCategoryName>
<ApplicationNumber>ANDA210552</ApplicationNumber>
<LabelerName>Tris Pharma, Inc.</LabelerName>
<SubstanceName>OLMESARTAN MEDOXOMIL</SubstanceName>
<StrengthNumber>40</StrengthNumber>
<StrengthUnit>mg/1</StrengthUnit>
<Pharm_Classes>Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2025-02-04</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20230520</StartMarketingDatePackage>
<EndMarketingDatePackage>20250131</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>Olmesartan Medoxomil Tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Olmesartan Medoxomil Tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents.</IndicationAndUsage>
<Description>Olmesartan medoxomil, a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. Olmesartan is a selective AT 1subtype angiotensin II receptor antagonist. Olmesartan medoxomil is described chemically as 2,3-dihydroxy-2-butenyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[ p-( o-1 H-tetrazol-5-ylphenyl)benzyl]imidazole-5-carboxylate, cyclic 2,3-carbonate. Its empirical formula is C 29H 30N 6O 6and its structural formula is:. Olmesartan medoxomil, USP is a white to light yellowish-white powder or crystalline powder with a molecular weight of 558.59. It is practically insoluble in water and sparingly soluble in methanol. Olmesartan Medoxomil Tablets, USP are available for oral use as film-coated tablets containing 5 mg, 20 mg, or 40 mg of olmesartan medoxomil and the following inactive ingredients: hydroxypropyl cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, hypromellose, talc, titanium dioxide, and (5 mg only) yellow iron oxide. Meets USP dissolution test 7.</Description>
</NDC>
<NDC>
<NDCCode>27808-277-02</NDCCode>
<PackageDescription>90 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (27808-277-02) </PackageDescription>
<NDC11Code>27808-0277-02</NDC11Code>
<ProductNDC>27808-277</ProductNDC>
<ProductTypeName>HUMAN PRESCRIPTION DRUG</ProductTypeName>
<ProprietaryName>Olmesartan Medoxomil</ProprietaryName>
<NonProprietaryName>Olmesartan Medoxomil</NonProprietaryName>
<DosageFormName>TABLET, FILM COATED</DosageFormName>
<RouteName>ORAL</RouteName>
<StartMarketingDate>20230520</StartMarketingDate>
<EndMarketingDate>20250131</EndMarketingDate>
<MarketingCategoryName>ANDA</MarketingCategoryName>
<ApplicationNumber>ANDA210552</ApplicationNumber>
<LabelerName>Tris Pharma, Inc.</LabelerName>
<SubstanceName>OLMESARTAN MEDOXOMIL</SubstanceName>
<StrengthNumber>40</StrengthNumber>
<StrengthUnit>mg/1</StrengthUnit>
<Pharm_Classes>Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC]</Pharm_Classes>
<Status>Deprecated</Status>
<LastUpdate>2025-02-04</LastUpdate>
<PackageNdcExcludeFlag>N</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>N</ProductNdcExcludeFlag>
<StartMarketingDatePackage>20230520</StartMarketingDatePackage>
<EndMarketingDatePackage>20250131</EndMarketingDatePackage>
<SamplePackage>N</SamplePackage>
<IndicationAndUsage>Olmesartan Medoxomil Tablets are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Olmesartan Medoxomil Tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents.</IndicationAndUsage>
<Description>Olmesartan medoxomil, a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. Olmesartan is a selective AT 1subtype angiotensin II receptor antagonist. Olmesartan medoxomil is described chemically as 2,3-dihydroxy-2-butenyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[ p-( o-1 H-tetrazol-5-ylphenyl)benzyl]imidazole-5-carboxylate, cyclic 2,3-carbonate. Its empirical formula is C 29H 30N 6O 6and its structural formula is:. Olmesartan medoxomil, USP is a white to light yellowish-white powder or crystalline powder with a molecular weight of 558.59. It is practically insoluble in water and sparingly soluble in methanol. Olmesartan Medoxomil Tablets, USP are available for oral use as film-coated tablets containing 5 mg, 20 mg, or 40 mg of olmesartan medoxomil and the following inactive ingredients: hydroxypropyl cellulose, lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, hypromellose, talc, titanium dioxide, and (5 mg only) yellow iron oxide. Meets USP dissolution test 7.</Description>
</NDC>
</NDCList>